Skip to Content

'
Christopher J. Logothetis

Present Title & Affiliation

Primary Appointment

Department Chair, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Roy M. and Phyllis Gough Huffington Clinical Research in Urologic Oncology Distinguished Chair, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1974 University of Athens School of Medicine, Athens, Greece, MD, Medicine

Postgraduate Training

1977-1979 Fellow, The University of Texas MD Anderson Cancer Center, Houston, TX
1975-1977 Clinical Residency, Cook County Hospital, Chicago, IL
1974-1975 Clinical Internship, Cook County Hospital, Chicago, IL

Board Certifications

1981 Medical Oncology Subspecialty Board
1978 American Board of Internal Medicine

Experience/Service

Academic Appointments

Chief, Section of Genitourinary Medical Oncology, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1986-1993

Endowed Positions

Bessie McGoldrick Professorship in Clinical Cancer Research, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1994-2002

Honors and Awards

1993-2003 CaP CURE Award
1992 Excellence in Teaching Clinical Oncology Award, The University of Texas M. D. Anderson Cancer Center Medical Oncology Fellows
1979 Clifton D. Howe Fellowship Achievement Award

Professional Memberships

American Association for Cancer Research
Member, 2001-present
American Medical Association
Member, 1978-present
American Society of Clinical Oncology
Member, 1978-present
Board of Scientific Advisors
Board Member, 2001-2011
CaP CURE Foundation Board of Directors
Board Member, 2003-2008
Harris County Medical Society
Member, 1978-present
Texas Medical Association
Member, 1978-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G, Huang J, True L, Gleave ME, Soule H, Logothetis C, Rubin MA. Aggressive variants of castration-resistant prostate cancer. Clin Cancer Res 20(11):2846-50, 6/2014. e-Pub 4/2014. PMCID: PMC4040316.
2. Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengeløv L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR, CA184-043 Investigators. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 15(7):700-12, 6/2014. e-Pub 5/2014. PMID: 24831977.
3. Efstathiou E, Titus M, Wen S, Hoang A, Karlou M, Ashe R, Tu SM, Aparicio A, Troncoso P, Mohler J, Logothetis CJ. Molecular Characterization of Enzalutamide-treated Bone Metastatic Castration-resistant Prostate Cancer. Eur Urol. e-Pub 5/2014. PMID: 24882673.
4. Gorlova O, Fedorov A, Logothetis C, Amos C, Gorlov I. Genes with a large intronic burden show greater evolutionary conservation on the protein level. BMC Evol Biol 14(1):50, 2014. e-Pub 3/2014. PMCID: PMC3995522.
5. Gorlov IP, Yang JY, Byun J, Logothetis C, Gorlova OY, Do KA, Amos C. How to get the most from microarray data: advice from reverse genomics. BMC Genomics 15(1):223, 2014. e-Pub 3/2014. PMCID: PMC3997969.
6. Araujo JC, Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, Wilding G, McCaffrey J, Serrano SV, Matveev VB, Efstathiou E, Oudard S, Morris MJ, Sizer B, Goebell PJ, Heidenreich A, de Bono JS, Begbie S, Hong JH, Richardet E, Gallardo E, Paliwal P, Durham S, Cheng S, Logothetis CJ. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol 14(13):1307-16, 12/2013. e-Pub 11/2013. NIHMSID: NIHMS592540.
7. Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, Shah N, Cai L, Efstathiou E, Logothetis C, Zheng D, Sawyers CL. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 155(6):1309-22, 12/2013. PMID: 24315100.
8. Basch E, Autio K, Ryan CJ, Mulders P, Shore N, Kheoh T, Fizazi K, Logothetis CJ, Rathkopf D, Smith MR, Mainwaring PN, Hao Y, Griffin T, Li S, Meyers ML, Molina A, Cleeland C. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol 14(12):1193-9, 11/2013. e-Pub 9/25/2013. PMID: 24075621.
9. Harland S, Staffurth J, Molina A, Hao Y, Gagnon DD, Sternberg CN, Cella D, Fizazi K, Logothetis CJ, Kheoh T, Haqq CM, de Bono JS, Scher HI, COU-AA-301 Investigators. Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. Eur J Cancer 49(17):3648-57, 11/2013. e-Pub 8/22/2013. PMID: 23973186.
10. Varkaris A, Gaur S, Parikh NU, Song JH, Dayyani F, Jin JK, Logothetis CJ, Gallick GE. Ligand-independent activation of MET through IGF-1/IGF-1R signaling. Int J Cancer 133(7):1536-46, 10/1/2013. e-Pub 4/17/2013. PMCID: PMC3713179.
11. Chan CH, Morrow JK, Li CF, Gao Y, Jin G, Moten A, Stagg LJ, Ladbury JE, Cai Z, Xu D, Logothetis CJ, Hung MC, Zhang S, Lin HK. Pharmacological Inactivation of Skp2 SCF Ubiquitin Ligase Restricts Cancer Stem Cell Traits and Cancer Progression. Cell 154(3):556-68, 8/1/2013. PMCID: PMC3845452.
12. Logothetis CJ, Gallick GE, Maity SN, Kim J, Aparicio A, Efstathiou E, Lin SH. Molecular Classification of Prostate Cancer Progression: Foundation for Marker-Driven Treatment of Prostate Cancer. Cancer Discov 3(8):849-61, 8/2013. e-Pub 6/28/2013. PMCID: PMC3926428.
13. Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ. Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer. Clin Cancer Res 19(13):3621-30, 7/1/2013. e-Pub 5/6/2013. PMCID: PMC3699964.
14. Logothetis CJ. Re: intratumor heterogeneity and branched evolution revealed by multiregion sequencing. Eur Urol 64(1):170, 7/2013. PMID: 23746321.
15. Dayyani F, Varkaris A, Araujo JC, Song JH, Chatterji T, Trudel GC, Logothetis CJ, Gallick GE. Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate cancer. Prostate 73(9):979-85, 6/2013. e-Pub 1/2013. PMCID: PMC4013833.
16. Lee YC, Jin JK, Cheng CJ, Huang CF, Song JH, Huang M, Brown WS, Zhang S, Yu-Lee LY, Yeh ET, McIntyre BW, Logothetis CJ, Gallick GE, Lin SH. Targeting Constitutively Activated β1 Integrin inhibits Prostate Cancer Metastasis. Mol Cancer Res 11(4):405-17, 4/2013. e-Pub 1/21/2013. PMCID: PMC3631285.
17. Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN, Lin CC, Srinivas S, Sella A, Schöffski P, Scheffold C, Weitzman AL, Hussain M. Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial. J Clin Oncol 31(4):412-9, 2/1/2013. e-Pub 11/19/2012. PMID: 23169517.
18. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE, COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368(2):138-48, 1/10/2013. e-Pub 12/10/2012. PMCID: PMC3683570.
19. McGuire SE, Lee AK, Cerne JZ, Munsell MF, Levy LB, Kudchadker RJ, Choi SL, Nguyen QN, Hoffman KE, Pugh TJ, Frank SJ, Corn PG, Logothetis CJ, Kuban DA. PSA Response to Neoadjuvant Androgen Deprivation Therapy Is a Strong Independent Predictor of Survival in High-Risk Prostate Cancer in the Dose-Escalated Radiation Therapy Era. Int J Radiat Oncol Biol Phys 85(1):e39-46, 1/1/2013. e-Pub 10/23/2012. PMCID: PMC3840533.
20. Efstathiou E, Karlou M, Wen S, Hoang A, Pettaway CA, Pisters LL, Maity S, Troncoso P, Logothetis CJ. Integrated Hedgehog signaling is induced following castration in human and murine prostate cancers. Prostate 73(2):153-61, 1/2013. e-Pub 7/2/2012. PMCID: PMC3878994.
21. Zhao H, Logothetis CJ, Gorlov IP, Zeng J, Dai J. Modified logistic regression models using gene coexpression and clinical features to predict prostate cancer progression. Comput Math Methods Med 2013:917502, 2013. e-Pub 12/2013. PMCID: PMC3866878.
22. Logothetis CJ, Basch E, Molina A, Fizazi K, North SA, Chi KN, Jones RJ, Goodman OB, Mainwaring PN, Sternberg CN, Efstathiou E, Gagnon DD, Rothman M, Hao Y, Liu CS, Kheoh TS, Haqq CM, Scher HI, de Bono JS. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol 13(12):1210-7, 12/2012. e-Pub 11/2012. PMID: 23142059.
23. Karlou M, Lu JF, Wu G, Maity S, Tzelepi V, Navone NM, Hoang A, Logothetis CJ, Efstathiou E. Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b. Prostate 72(15):1638-47, 11/2012. e-Pub 3/2012. PMID: 22457212.
24. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB, Sternberg CN, Li JH, Kheoh T, Haqq CM, de Bono JS, for the COU-AA-301 Investigators. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13(10):983-992, 10/2012. e-Pub 9/2012. PMID: 22995653.
25. Som A, Tu SM, Liu J, Wang X, Qiao W, Logothetis C, Corn PG. Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials. Br J Cancer 107(9):1547-53, 10/2012. e-Pub 10/2012. PMID: 23033003.
26. Tu SM, Som A, Tu B, Logothetis CJ, Lee MH, Yeung SC. Effect of Paget's disease of bone (osteitis deformans) on the progression of prostate cancer bone metastasis. Br J Cancer. e-Pub 7/17/2012. PMID: 22805323.
27. Gorlov IP, Byun J, Logothetis CJ. In silico functional profiling of individual prostate cancer tumors: many genes, few functions. Cancer Genomics Proteomics 9(3):109-14, 5/2012. PMCID: PMC3922615.
28. Sharma P, Logothetis C. Prostate cancer: Combination of vaccine plus ipilimumab-safety and toxicity. Nat Rev Urol. e-Pub 5/2012. PMID: 22565371.
29. Zurita AJ, George DJ, Shore ND, Liu G, Wilding G, Hutson TE, Kozloff M, Mathew P, Harmon CS, Wang SL, Chen I, Chow Maneval E, Logothetis CJ. Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial. Ann Oncol 23(3):688-94, 3/2012. e-Pub 8/5/2011. PMID: 21821830.
30. Ye X, Lee YC, Choueiri M, Chu K, Huang CF, Tsai WW, Kobayashi R, Logothetis CJ, Yu-Lee LY, Lin SH. Aberrant expression of katanin p60 in prostate cancer bone metastasis. Prostate 72(3):291-300, 2/2012. e-Pub 6/2011. PMCID: PMC3179562.
31. Efstathiou E, Titus M, Tsavachidou D, Tzelepi V, Wen S, Hoang A, Molina A, Chieffo N, Smith LA, Karlou M, Troncoso P, Logothetis CJ. Effects of Abiraterone Acetate on Androgen Signaling in Castrate-Resistant Prostate Cancer in Bone. J Clin Oncol 30(6):637-43, 2/2012. e-Pub 12/2011. PMCID: PMC3295561.
32. Tzelepi V, Zhang J, Lu JF, Kleb B, Wu G, Wan X, Hoang A, Efstathiou E, Sircar K, Navone NM, Troncoso P, Liang S, Logothetis CJ, Maity SN, Aparicio AM. Modeling a Lethal Prostate Cancer Variant with Small-Cell Carcinoma Features. Clin Cancer Res 18(3):666-77, 2/2012. e-Pub 12/2011. PMCID: PMC3923417.
33. Zurita AJ, Jonasch E, Wang X, Khajavi M, Yan S, Du DZ, Xu L, Herynk MH, McKee KS, Tran HT, Logothetis CJ, Tannir NM, Heymach JV. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol 23(1):46-52, 1/2012. e-Pub 4/4/2011. PMCID: PMC3276320.
34. Araujo JC, Mathew P, Armstrong AJ, Braud EL, Posadas E, Lonberg M, Gallick GE, Trudel GC, Paliwal P, Agrawal S, Logothetis CJ. Dasatinib combined with docetaxel for castration-resistant prostate cancer: Results from a phase 1-2 study. Cancer 118(1):63-71, 1/2012. e-Pub 7/2011. PMCID: PMC3898168.
35. Gorlov IP, Logothetis CJ, Fang S, Gorlova OY, Amos C. Building a statistical model for predicting cancer genes. PLoS One 7(11):e49175, 2012. e-Pub 11/2012. PMCID: PMC3499550.
36. Dayyani F, Parikh NU, Varkaris AS, Song JH, Moorthy S, Chatterji T, Maity SN, Wolfe AR, Carboni JM, Gottardis MM, Logothetis CJ, Gallick GE. Combined Inhibition of IGF-1R/IR and Src Family Kinases Enhances Antitumor Effects in Prostate Cancer by Decreasing Activated Survival Pathways. PLoS One 7(12):e51189, 2012. e-Pub 12/2012. PMCID: PMC3530555.
37. Kim J, Amos CI, Logothetis C. 5α-Reductase inhibitors for prostate-cancer prevention. N Engl J Med 365(24):2340, 12/15/2011. PMID: 22168662.
38. Varkaris A, Corn PG, Gaur S, Dayyani F, Logothetis CJ, Gallick GE. The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin Investig Drugs 20(12):1677-84, 12/2011. e-Pub 10/2011. PMCID: PMC4020016.
39. Dayyani F, Gallick GE, Logothetis CJ, Corn PG. Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer. J Natl Cancer Inst 103(22):1665-1675, 11/2011. e-Pub 9/2011. PMID: 21917607.
40. Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, Kalyana-Sundaram S, Sam L, Balbin OA, Quist MJ, Barrette T, Everett J, Siddiqui J, Kunju LP, Navone N, Araujo JC, Troncoso P, Logothetis CJ, Innis JW, Smith DC, Lao CD, Kim SY, Roberts JS, Gruber SB, Pienta KJ, Talpaz M, Chinnaiyan AM. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 3(111):111ra121, 11/2011. PMCID: PMC3476478.
41. Staquicini FI, Cardó-Vila M, Kolonin MG, Trepel M, Edwards JK, Nunes DN, Sergeeva A, Efstathiou E, Sun J, Almeida NF, Tu SM, Botz GH, Wallace MJ, O'Connell DJ, Krajewski S, Gershenwald JE, Molldrem JJ, Flamm AL, Koivunen E, Pentz RD, Dias-Neto E, Setubal JC, Cahill DJ, Troncoso P, Do KA, Logothetis CJ, Sidman RL, Pasqualini R, Arap W. Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients. Proc Natl Acad Sci U S A 108(46):18637-18642, 11/2011. e-Pub 11/2011. PMCID: PMC3219136.
42. Logothetis CJ, Efstathiou E, Manuguid F, Kirkpatrick P. Abiraterone acetate. Nat Rev Drug Discov 10(8):573-4, 8/2011. e-Pub 8/2011. PMID: 21804589.
43. Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bubley GJ, Logothetis CJ, Kheoh T, Kilian C, Haqq CM, Molina A, Small EJ. Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic Response. Clin Cancer Res 17(14):4854-61, 7/2011. e-Pub 6/2011. PMCID: PMC3657705.
44. Tzelepi V, Karlou M, Wen S, Hoang A, Logothetis C, Troncoso P, Efstathiou E. Expression of hedgehog pathway components in prostate carcinoma microenvironment: shifting the balance towards autocrine signalling. Histopathology 58(7):1037-47, 6/2011. PMID: 21707705.
45. Aparicio A, Tzelepi V, Araujo JC, Guo CC, Liang S, Troncoso P, Logothetis CJ, Navone NM, Maity SN. Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles. Prostate 71(8):846-56, 6/2011. e-Pub 11/2010. PMCID: PMC3883511.
46. Tzelepi V, Efstathiou E, Wen S, Troncoso P, Karlou M, Pettaway CA, Pisters LL, Hoang A, Logothetis CJ, Pagliaro LC. Persistent, Biologically Meaningful Prostate Cancer After 1 Year of Androgen Ablation and Docetaxel Treatment. J Clin Oncol 29(18):2574-81, 6/2011. e-Pub 5/2011. PMCID: PMC3138635.
47. Logothetis CJ. When 'dueling technologies' are mistaken for progress. BJU Int 107(11):1699-700, 6/2011. PMCID: PMC3922611.
48. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI, COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21):1995-2005, 5/2011. PMCID: PMC3471149.
49. Bracarda S, Logothetis C, Sternberg CN, Oudard S. Current and emerging treatment modalities for metastatic castration-resistant prostate cancer. BJU Int 107 Suppl 2:13-20, 4/2011. PMID: 21382150.
50. Fitzpatrick JM, Bellmunt J, Dreicer R, Fleshner NE, Logothetis CJ, Moul JW, Tombal B, Zlotta A. Maximizing outcomes in genitourinary cancers across the treatment continuum. BJU Int 107 Suppl 2:1-12, 4/2011. PMID: 21382149.
51. Li J, Ding Z, Wang Z, Lu JF, Maity SN, Navone NM, Logothetis CJ, Mills GB, Kim J. Androgen regulation of 5α-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention. PLoS One 6(12):e28840, 2011. e-Pub 12/2011. PMCID: PMC3237548.
52. Aparicio A, Tzelepi V, Araujo JC, Guo CC, Liang S, Troncoso P, Logothetis CJ, Navone NM, Maity SN. Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: Morphological, immunohistochemical, and gene expression profiles. Prostate. e-Pub 11/17/2010. PMID: 21086505.
53. Prantl L, Muehlberg F, Navone NM, Song YH, Vykoukal J, Logothetis CJ, Alt EU. Adipose tissue-derived stem cells promote prostate tumor growth. Prostate 70(15):1709-15, 11/2010. e-Pub 6/2010. NIHMSID: NIHMS612155.
54. Araujo J, Logothetis C. Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors. Cancer Treat Rev 36(6):492-500, 10/2010. e-Pub 3/2010. PMID: 20226597.
55. Zhao H, Logothetis CJ, Gorlov IP. Usefulness of the top-scoring pairs of genes for prediction of prostate cancer progression. Prostate Cancer Prostatic Dis 13(3):252-9, 9/2010. e-Pub 4/2010. NIHMSID: NIHMS610680.
56. Huang CF, Lira C, Chu K, Bilen MA, Lee YC, Ye X, Kim SM, Ortiz A, Wu FL, Logothetis CJ, Yu-Lee LY, Lin SH. Cadherin-11 increases migration and invasion of prostate cancer cells and enhances their interaction with osteoblasts. Cancer Res 70(11):4580-9, 6/2010. PMCID: PMC2923552.
57. Efstathiou E, Abrahams NA, Tibbs RF, Wang X, Pettaway CA, Pisters LL, Mathew PF, Do KA, Logothetis CJ, Troncoso P. Morphologic Characterization of Preoperatively Treated Prostate Cancer: Toward a Post-Therapy Histologic Classification. Eur Urol 57(6):1030-8, 6/2010. e-Pub 10/2009. PMCID: PMC2962710.
58. Tu SM, Lin SH, Podoloff DA, Logothetis CJ. Multimodality Therapy: Bone-targeted Radioisotope Therapy of Prostate Cancer. Clin Adv Hematol Oncol 8(5):341-51, 5/2010. PMID: 20551894.
59. Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, Sun J, Ku G, Troncoso P, Logothetis CJ, Allison JP, Sharma P. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res 16(10):2861-71, 5/2010. PMCID: PMC2919850.
60. Thompson TC, Tahir SA, Li L, Watanabe M, Naruishi K, Yang G, Kadmon D, Logothetis CJ, Troncoso P, Ren C, Goltsov A, Park S. The role of caveolin-1 in prostate cancer: clinical implications. Prostate Cancer Prostatic Dis 13(1):6-11, 3/2010. PMID: 19581923.
61. Efstathiou E, Logothetis CJ. A new therapy paradigm for prostate cancer founded on clinical observations. Clin Cancer Res 16(4):1100-7, 2/2010. PMCID: PMC3891669.
62. Gorlov IP, Sircar K, Zhao H, Maity SN, Navone NM, Gorlova OY, Troncoso P, Pettaway CA, Byun JY, Logothetis CJ. Prioritizing genes associated with prostate cancer development. BMC Cancer 10:599, 2010. e-Pub 11/2010. PMCID: PMC2988752.
63. Byun J, Logothetis CJ, Gorlov IP. Housekeeping genes in prostate tumorigenesis. Int J Cancer 125(11):2603-8, 12/2009. NIHMSID: NIHMS143561.
64. Araujo JC, Poblenz A, Corn P, Parikh NU, Starbuck MW, Thompson JT, Lee F, Logothetis CJ, Darnay BG. Dasatinib inhibits both osteoclast activation and prostate cancer PC-3 cell-induced osteoclast formation. Cancer Biol Ther 8(22):2151-7, 11/2009. PMCID: PMC4073296.
65. Efstathiou E, Kim J, Logothetis CJ. Informative clinical investigation: a demanding taskmaster. J Clin Oncol 27(30):4937-8, 10/2009. PMID: 19720892.
66. Gorlov IP, Byun J, Gorlova OY, Aparicio AM, Efstathiou E, Logothetis CJ. Candidate pathways and genes for prostate cancer: a meta-analysis of gene expression data. BMC Med Genomics 2:48, 8/2009. PMCID: PMC2731785.
67. Daliani DD, Tannir NM, Papandreou CN, Wang X, Swisher S, Wood CG, Swanson DA, Logothetis CJ, Jonasch E. Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma. BJU Int 104(4):456-60, 8/2009. PMID: 19338544.
68. Tu SM, Mathew P, Wong FC, Jones D, Johnson MM, Logothetis CJ. Phase I Study of Concurrent Weekly Docetaxel and Repeated Samarium-153 Lexidronam in Patients With Castration-Resistant Metastatic Prostate Cancer. J Clin Oncol 27(20):3319-3324, 7/2009. PMID: 19414670.
69. Efstathiou E, Logothetis CJ. Prostate cancer: Thalidomide for prostate cancer: is there progress? Nat Rev Urol 6(5):248-50, 5/2009. PMID: 19424170.
70. Gnjatic S, Altorki NK, Tang DN, Tu SM, Kundra V, Ritter G, Old LJ, Logothetis CJ, Sharma P. NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells. Clin Cancer Res 15(6):2130-9, 3/2009. PMID: 19276258.
71. Pataer A, Swisher SG, Roth JA, Logothetis CJ, Corn P. Inhibition of RNA-dependent protein kinase (PKR) leads to cancer cell death and increases chemosensitivity. Cancer Biol Ther 8(3):245-52, 2/2009. PMCID: PMC2854203.
72. Tsavachidou D, McDonnell TJ, Wen S, Wang X, Vakar-Lopez F, Pisters LL, Pettaway CA, Wood CG, Do KA, Thall PF, Stephens C, Efstathiou E, Taylor R, Menter DG, Troncoso P, Lippman SM, Logothetis CJ, Kim J. Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst 101(5):306-20, 2/2009. PMCID: PMC2734116.
73. Gorlov IP, Gallick GE, Gorlova OY, Amos C, Logothetis CJ. GWAS meets microarray: are the results of genome-wide association studies and gene-expression profiling consistent? Prostate cancer as an example. PLoS One 4(8):e6511, 2009. PMCID: PMC2714961.
74. Millikan RE, Wen S, Pagliaro LC, Brown MA, Moomey B, Do KA, Logothetis CJ. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol 26(36):5936-42, 12/2008. PMID: 19029421.
75. Mathew P, Thall PF, Wen S, Bucana C, Jones D, Horne E, Oh WK, Morris MJ, Lee YC, Logothetis CJ, Lin SH, Fidler IJ. Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer. Br J Cancer 99(9):1426-32, 10/2008. PMID: 18841158.
76. Liakou CI, Kamat A, Tang DN, Chen H, Sun J, Troncoso P, Logothetis C, Sharma P. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A 105(39):14987-92, 9/30/2008. PMID: 18818309.
77. Araujo J, Logothetis C. Targeting Src signaling in metastatic bone disease. Int J Cancer 124(1):1-6, 9/2008. PMID: 18942061.
78. Chu K, Cheng CJ, Ye X, Lee YC, Zurita AJ, Chen DT, Yu-Lee LY, Zhang S, Yeh ET, Hu MC, Logothetis CJ, Lin SH. Cadherin-11 promotes the metastasis of prostate cancer cells to bone. Mol Cancer Res 6(8):1259-67, 8/2008. PMCID: PMC2643879.
79. Li ZG, Mathew P, Yang J, Starbuck MW, Zurita AJ, Liu J, Sikes C, Multani AS, Efstathiou E, Lopez A, Wang J, Fanning TV, Prieto VG, Kundra V, Vazquez ES, Troncoso P, Raymond AK, Logothetis CJ, Lin SH, Maity S, Navone NM. Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest 118(8):2697-710, 7/2008. PMCID: PMC2447924.
80. Lin SH, Lee YC, Choueiri MB, Wen S, Mathew P, Ye X, Do KA, Navone NM, Kim J, Tu SM, Yu-Lee LY, Logothetis CJ. Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer. Clin Cancer Res 14(12):3729-36, 6/2008. PMCID: PMC2562877.
81. Lin SH, Cheng CJ, Lee YC, Ye X, Tsai WW, Kim J, Pasqualini R, Arap W, Navone NM, Tu SM, Hu M, Yu-Lee LY, Logothetis CJ. A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation. Oncogene 27(39):5195-203, 5/2008. PMCID: PMC2562662.
82. Logothetis CJ, Navone NM, Lin SH. Understanding the biology of bone metastases: Key to the effective treatment of prostate cancer. Clin Cancer Res 14(6):1599-602, 3/2008. PMID: 18347159.
83. Fizazi K, Le Maitre A, Hudes G, Berry WR, Kelly WK, Eymard JC, Logothetis CJ, Pignon JP, Michiels S, Meta-analysis of Estramustine in Prostate Cancer (MECaP) Trialists' Collaborative Group. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol 8(11):994-1000, 11/2007. e-Pub 10/2007. PMID: 17942366.
84. Thall PF, Wooten LH, Logothetis CJ, Millikan RE, Tannir NM. Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoring. Stat Med 26(26):4687-702, 11/2007. e-Pub 4/2007. PMID: 17427204.
85. Mao S, Daliani DD, Wang X, Thall PF, Do KA, Perez CA, Brown MA, Bouchillon K, Carter CM, Logothetis CJ, Kim J. Employing the treatment-free interval of intermittent androgen ablation to screen candidate prostate cancer therapies. Prostate 67(15):1677-85, 11/2007. PMID: 17879948.
86. Mathew P, Thall PF, Bucana CD, Oh WK, Morris MJ, Jones DM, Johnson MM, Wen S, Pagliaro LC, Tannir NM, Tu SM, Meluch AA, Smith L, Cohen L, Kim SJ, Troncoso P, Fidler IJ, Logothetis CJ. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res 13(19):5816-24, 10/2007. PMID: 17908974.
87. Li ZG, Yang J, Vazquez ES, Rose D, Vakar-Lopez F, Mathew P, Lopez A, Logothetis CJ, Lin SH, Navone NM. Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone. Oncogene 27(5):596-603, 8/2007. PMID: 17700537.
88. Chen N, Ye XC, Chu K, Navone NM, Sage EH, Yu-Lee LY, Logothetis CJ, Lin SH. A Secreted Isoform of ErbB3 Promotes Osteonectin Expression in Bone and Enhances the Invasiveness of Prostate Cancer Cells. Cancer Res 67(14):6544-8, 7/2007. PMCID: PMC2000837.
89. van Adelsberg J, Gann P, Ko AT, Damber JE, Logothetis C, Marberger M, Schmitz-Drager BJ, Tubaro A, Harms CJ, Roehrborn C. The VIOXX in prostate cancer prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups. Curr Med Res Opin 23(9):2063-2070, 7/2007. PMID: 17651539.
90. Liakou CI, Narayanan S, Ng Tang D, Logothetis CJ, Sharma P. Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer (Review). Cancer Immun 7:10 (Review), 6/2007. PMCID: PMC2935746.
91. Efstathiou E, Troncoso P, Wen S, Do KA, Pettaway CA, Pisters LL, McDonnell TJ, Logothetis CJ. Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res 13(4):1224-31, 2/2007. PMID: 17317833.
92. Tannir NM, Cohen L, Wang X, Thall P, Mathew PF, Jonasch E, Siefker-Radtke A, Pagliaro LC, Ng CS, Logothetis C. Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. Cancer 107:2254-61, 11/2006. PMID: 17029276.
93. Motzer RJ, Bolger GB, Boston B, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Jonasch E, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Pohar K, Redman BG, Robertson CN, Samlowski WE, Sheinfeld J; National Comprehensive Cancer Network. Kidney cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 4(10):1072-81, 11/2006. PMID: 17112454.
94. Efstathiou E, Logothetis CJ. Review of late complications of treatment and late relapse in testicular cancer. J Natl Compr Canc Netw 4(10):1059-70, 11/2006. PMID: 17112453.
95. Subbarayan V, Krieg P, Hsi LC, Kim J, Yang P, Sabichi AL, Llansa N, Mendoza G, Logothetis CJ, Newman RA, Lippman SM, Menter DG. 15-Lipoxygenase-2 gene regulation by its product 15-(S)-hydroxyeicosatetraenoic acid through a negative feedback mechanism that involves peroxisome proliferator-activated receptor gamma. Oncogene 25:6015-25, 9/2006. PMID: 16682954.
96. Spurgers KB, Gold DL, Coombes KR, Bohnenstiehl NL, Mullins B, Meyn RE, Logothetis CJ, McDonnell TJ. Identification of Cell Cycle Regulatory Genes as Principal Targets of p53-mediated Transcriptional Repression. J Biol Chem 281(35):25134-42, 9/2006. PMID: 16798743.
97. Mathew P, Logothetis CJ, Dieringer PY, Chen I, Pagliaro LC, Bekele BN, Zhou X, Daliani DD. Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer. Clin Genitourin Cancer 5(2):144-9, 9/2006. PMID: 17026803.
98. Kim SJ, Uehara H, Yazici S, Busby JE, Nakamura T, He J, Maya M, Logothetis C, Mathew P, Wang X, Do KA, Fan D, Fidler IJ. Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. J Natl Cancer Inst 98(11):783-93, 6/2006. PMID: 16757703.
99. Leibovici D, Kamat AM, Pettaway CA, Pagliaro L, Rosser CJ, Logothetis C, Pisters LL. Cystoprostatectomy for effective palliation of symptomatic bladder invasion by prostate cancer. J Urol 174(6):2186-90, 12/2005. PMID: 16280761.
100. Tu SM, Kim J, Pagliaro LC, Vakar-Lopez F, Wong FC, Wen S, General R, Podoloff DA, Lin SH, Logothetis CJ. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol 23(31):7904-10, 11/2005. PMID: 16258090.
101. Strom SS, Wang X, Pettaway CA, Logothetis CJ, Yamamura Y, Do KA, Babaian RJ, Troncoso P. Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res 11(19 Pt 1):6889-94, 10/2005. PMID: 16203779.
102. Kim J, Yang P, Suraokar M, Sabichi AL, Llansa ND, Mendoza G, Subbarayan V, Logothetis CJ, Newman RA, Lippman SM, Menter DG. Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products. Cancer Res 65(14):6189-98, 7/2005. PMID: 16024620.
103. Cho-Vega JH, Troncoso P, Do KA, Rago C, Wang X, Tsavachidis S, Medeiros LJ, Spurgers K, Logothetis C, McDonnell TJ. Combined laser capture microdissection and serial analysis of gene expression from human tissue samples. Mod Pathol 18(4):577-84, 4/2005. PMID: 15529182.
104. Subbarayan V, Xu XC, Kim J, Yang P, Hoque A, Sabichi AL, Llansa N, Mendoza G, Logothetis CJ, Newman RA, Lippman SM, Menter DG. Inverse relationship between 15-lipoxygenase-2 and PPAR-gamma gene expression in normal epithelia compared with tumor epithelia. Neoplasia 7(3):280-93, 3/2005. PMCID: PMC1501140.
105. Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 5(1):21-8, 1/2005. PMID: 15630412.
106. Wyatt RB, Sanchez-Ortiz RF, Wood CG, Ramirez E, Logothetis C, Pettaway CA. Prognostic factors for survival among Caucasian, African-American and Hispanic men with androgen-independent prostate cancer. J Natl Med Assoc 96(12):1587-93, 12/2004. PMID: 15622688.
107. Subbarayan V, Sabichi AL, Kim J, Llansa N, Logothetis CJ, Lippman SM, Menter DG. Differential peroxisome proliferator-activated receptor-gamma isoform expression and agonist effects in normal and malignant prostate cells. Cancer Epidemiol Biomarkers Prev 13(11 Pt 1):1710-6, 11/2004. PMID: 15533897.
108. Assikis VJ, Do KA, Wen S, Wang X, Cho-Vega JH, Brisbay S, Lopez R, Logothetis CJ, Troncoso P, Papandreou CN, McDonnell TJ. Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potential. Clin Cancer Res 10(20):6770-8, 10/2004. PMID: 15501953.
109. Fizazi K, Culine S, Kramar A, Amato RJ, Bouzy J, Chen I, Droz JP, Logothetis CJ. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol 22(19):3868-76, 10/2004. PMID: 15302906.
110. Strom SS, Gu Y, Zhang H, Troncoso P, Babaian RJ, Pettaway CA, Shete S, Spitz MR, Logothetis CJ. Androgen receptor polymorphisms and risk of biochemical failure among prostatectomy patients. Prostate 60(4):343-51, 9/2004. PMID: 15264247.
111. Fizazi K, Sikes CR, Kim J, Yang J, Martinez LA, Olive MC, Logothetis CJ, Navone NM. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer. Anticancer Res 24(5A):2897-903, 9/2004. PMID: 15517894.
112. Papandreou CN, Logothetis CJ. Bortezomib as a potential treatment for prostate cancer. Cancer Res 64(15):5036-43, 8/2004. PMID: 15289299.
113. Mathew P, Thall PF, Jones D, Perez C, Bucana C, Troncoso P, Kim SJ, Fidler IJ, Logothetis C. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. J Clin Oncol 22(16):3323-9, 8/2004. PMID: 15310776.
114. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22(11):2108-21, 6/2004. PMID: 15169797.
115. Mathew P, Fidler IJ, Logothetis CJ. Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer. Semin Oncol 31:24-9, 4/2004. PMID: 15176001.
116. Pisters LL, Pettaway CA, Troncoso P, McDonnell TJ, Stephens LC, Wood CG, Do KA, Brisbay SM, Wang X, Hossan EA, Evans RB, Soto C, Jacobson MG, Parker K, Merritt JA, Steiner MS, Logothetis CJ. Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. Clin Cancer Res 10(8):2587-93, 4/2004. PMID: 15102659.
117. Salas TR, Kim J, Vakar-Lopez F, Sabichi AL, Troncoso P, Jenster G, Kikuchi A, Chen SY, Shemshedini L, Suraokar M, Logothetis CJ, DiGiovanni J, Lippman SM, Menter DG. Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity. J Biol Chem 279(18):19191-200, 4/2004. PMID: 14985354.
118. Spurgers KB, Coombes KR, Meyn RE, Gold DL, Logothetis CJ, Johnson TJ, McDonnell TJ. A comprehensive assessment of p53-responsive genes following adenoviral-p53 gene transfer in Bcl-2-expressing prostate cancer cells. Oncogene 23(9):1712-23, 3/2004. PMID: 14647426.
119. Zurita AJ, Troncoso P, Cardo-Vila M, Logothetis CJ, Pasqualini R, Arap W. Combinatorial screenings in patients: the interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancer. Cancer Res 64(2):435-9, 1/2004. PMID: 14744752.
120. Siefker-Radtke AO, Walsh GL, Pisters LL, Shen Y, Swanson DA, Logothetis CJ, Millikan RE. Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol 171(1):145-8, 1/2004. PMID: 14665863.
121. Williams S, Pettaway C, Song R, Papandreou C, Logothetis C, McConkey DJ. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther 2(9):835-43, 9/2003. PMID: 14555702.
122. Logothetis CJ. Foundation for the integration of biologically based therapy in the management of prostate cancer. Prostate 57(1):32-8, 9/2003. PMID: 12886521.
123. Tu SM, Millikan RE, Pagliaro LC, Daliani D, Papandreou CN, Kim J, Chen DT, Williams DL, Logothetis CJ. Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, alpha-interferon, cisplatin (FAP). Urol Oncol 21(5):342-8, 9/2003. PMID: 14670540.
124. Fizazi K, Yang J, Peleg S, Sikes CR, Kreimann EL, Daliani D, Olive M, Raymond KA, Janus TJ, Logothetis CJ, Karsenty G, Navone NM. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res 9(7):2587-97, 7/2003. PMID: 12855635.
125. Pagliaro LC, Delpassand ES, Williams D, Millikan RE, Tu SM, Logothetis CJ. A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases. Cancer 97(12):2988-94, 6/2003. PMID: 12784333.
126. Bruckheimer EM, Spurgers K, Weigel NL, Logothetis C, McDonnell TJ. Regulation of Bcl-2 expression by dihydrotestosterone in hormone sensitive LNCaP-FGC prostate cancer cells. J Urol 169(4):1553-7, 4/2003. PMID: 12629413.
127. Uehara H, Kim SJ, Karashima T, Shepherd DL, Fan D, Tsan R, Killion JJ, Logothetis C, Mathew P, Fidler IJ. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst 95(6):458-70, 3/2003. PMID: 12644539.
128. Millikan R, Thall PF, Lee SJ, Jones D, Cannon MW, Kuebler JP, Wade J, 3rd, Logothetis CJ. Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer. J Clin Oncol 21(5):878-83, 3/2003. PMID: 12610188.
129. Daliani DD, Assikis V, Tu SM, Papandreou CN, Pagliaro LC, Holtkamp T, Wang X, Thall PF, Logothetis CJ. Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma. Cancer 97(3):561-7, 2/2003. PMID: 12548597.
130. Logothetis C, Tu SM, Navone N. Targeting prostate cancer bone metastases. Cancer 97(3):785-8, 2/2003. PMID: 12548576.
131. Mintz PJ, Kim J, Do KA, Wang X, Zinner RG, Cristofanilli M, Arap MA, Hong WK, Troncoso P, Logothetis CJ, Pasqualini R, Arap W. Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol 21(1):57-63, 1/2003. PMID: 12496764.
132. Pentz RD, Flamm AL, Pasqualini R, Logothetis CJ, Arap W. Revisiting ethical guidelines for research with terminal wean and brain-dead participants. Hastings Cent Rep 33(1):20-6, 1/2003. PMID: 12613384.
133. Kim J, Millikan RE, Smith TL, Tu SM, Pagliaro LC, Logothetis CJ. Treating refractory advanced or metastatic urothelial carcinoma with interleukin-2: a phase II study. Urol Oncol 21(1):21-6, 1/2003. PMID: 12684123.
134. Volpert O, Luo W, Liu TJ, Estrera VT, Logothetis C, Lin SH. Inhibition of prostate tumor angiogenesis by the tumor suppressor CEACAM1. J Biol Chem 277(38):35696-702, 9/2002. PMID: 12122002.
135. Logothetis CJ. Challenge of locally persistent prostate cancer: an unresolved clinical dilemma. J Clin Oncol 20(15):3187, 8/2002. PMID: 12149287.
136. Pu YS, Do KA, Luo W, Logothetis CJ, Lin SH. Enhanced suppression of prostate tumor growth by combining C-CAM1 gene therapy and angiogenesis inhibitor TNP-470. Anticancer Drugs 13(7):743-9, 8/2002. PMID: 12187331.
137. Martinez LA, Yang J, Vazquez ES, Rodriguez-Vargas Mdel C, Olive M, Hsieh JT, Logothetis CJ, Navone NM. p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells. Carcinogenesis 23(8):1289-96, 8/2002. PMID: 12151346.
138. Tu SM, Lin SH, Logothetis CJ. Stem-cell origin of metastasis and heterogeneity in solid tumours. Lancet Oncol 3(8):508-13, 8/2002. PMID: 12147437.
139. Pagliaro LC, Millikan RE, Tu SM, Williams D, Daliani D, Papandreou CN, Logothetis CJ. Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma. J Clin Oncol 20(13):2965-70, 7/2002. PMID: 12089226.
140. Papandreou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A, Troncoso P, Logothetis CJ. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 20(14):3072-80, 7/2002. PMID: 12118020.
141. Fizazi K, Prow DM, Do KA, Wang X, Finn L, Kim J, Daliani D, Papandreou CN, Tu SM, Millikan RE, Pagliaro LC, Logothetis CJ, Amato RJ. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours. Br J Cancer 86(10):1555-60, 5/2002. PMID: 12085204.
142. Tu SM, Reyes A, Maa A, Bhowmick D, Pisters LL, Pettaway CA, Lin SH, Troncoso P, Logothetis CJ. Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features. Cancer 94(10):2610-7, 5/2002. PMID: 12173328.
143. Siefker-Radtke AO, Millikan RE, Tu SM, Moore DF, Jr, Smith TL, Williams D, Logothetis CJ. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol 20(5):1361-7, 3/2002. PMID: 11870180.
144. Fizazi K, Martinez LA, Sikes CR, Johnston DA, Stephens LC, McDonnell TJ, Logothetis CJ, Trapman J, Pisters LL, Ordonez NG, Troncoso P, Navone NM. The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer. Clin Cancer Res 8(3):775-81, 3/2002. PMID: 11895908.
145. Fizazi K, Chen I, Logothetis CJ. Germ-cell tumor survivors: the price for cure. Ann Oncol 13(2):187-9, 2/2002. PMID: 11885993.
146. Plonowski A, Schally AV, Nagy A, Groot K, Krupa M, Navone NM, Logothetis C. Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207. Cancer Lett 176(1):57-63, 2/2002. PMID: 11790454.
147. Arap W, Kolonin MG, Trepel M, Lahdenranta J, Cardo-Vila M, Giordano RJ, Mintz PJ, Ardelt PU, Yao VJ, Vidal CI, Chen L, Flamm A, Valtanen H, Weavind LM, Hicks ME, Pollock RE, Botz GH, Bucana CD, Koivunen E, Cahill D, Troncoso P, Baggerly KA, Pentz RD, Do KA, Logothetis CJ, Pasqualini R. Steps toward mapping the human vasculature by phage display. Nat Med 8(2):121-7, 2/2002. PMID: 11821895.
148. Fizazi K, Do KA, Wang X, Finn L, Logothetis CJ, Amato RJ. A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trial. Ann Oncol 13(1):125-34, 2002. PMID: 11863094.
149. Pu, Y-S, Do K-A, Luo W, Logothetis CJ, Lin S-H. Enhanced suppression of prostate tumor growth by combining C-CAM1 gene therapy and angiogenesis inhibitor TNP-470. Anti-Cancer Drugs 13:1-8, 2002.
150. Coombes KR, Zhang L, Bueso-Ramos C, Brisbay S, Logothetis C, Roth J, Keating MJ, McDonnell TJ. TAD: a web interface and database for tissue microarrays. Appl Bioinformatics 1(3):155-8, 2002. PMID: 15130842.
151. Newman RA, Yang J, Raymond M, Finlay V, Cabral F, Vourloumis D, Stephens LC, Troncoso P, Wu X, Logothetis CJ, Nicolaou KC, Navone NM. Antitumor efficacy of 26-fluoroepothilone B against human prostate cancer xenografts. Cancer Chemother Pharmacol 48(4):319-26, 10/2001. PMID: 11710633.
152. Merritt JA, Roth JA, Logothetis CJ. Clinical evaluation of adenoviral-mediated p53 gene transfer: review of INGN 201 studies. Semin Oncol 28(5 Suppl 16):105-14, 10/2001. PMID: 11706402.
153. Millikan R, Dinney C, Swanson D, Sweeney P, Ro JY, Smith TL, Williams D, Logothetis C. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol 19(20):4005-13, 10/2001. PMID: 11600601.
154. Fizazi K, Amato RJ, Beuzeboc P, Petit N, Bouhour D, Thiss A, Rebischung C, Chevreau C, Logothetis CJ, Droz JP. Germ cell tumors in patients infected by the human immunodeficiency virus. Cancer 92(6):1460-7, 9/2001. PMID: 11745223.
155. Honda T, Gjertsen BT, Spurgers KB, Briones F, Lee SJ, Hobbs ML, Meyn RE, Roth JA, Logothetis C, McDonnell TJ. Restoration of bax in prostate cancer suppresses tumor growth and augments therapeutic cell death induction. Anticancer Res 21(5):3141-6, 9/2001. PMID: 11848465.
156. Millikan RE, Plunkett WK, Smith TL, Williams DL, Logothetis CJ. Gemcitabine modulation of alkylator therapy: a phase I trial of escalating gemcitabine added to fixed doses of ifosfamide and doxorubicin. Cancer 92(1):194-9, 7/2001. PMID: 11443627.
157. Yang J, Fizazi K, Peleg S, Sikes CR, Raymond AK, Jamal N, Hu M, Olive M, Martinez LA, Wood CG, Logothetis CJ, Karsenty G, Navone NM. Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Cancer Res 61(14):5652-9, 7/2001. PMID: 11454720.
158. Logothetis CJ, Wu KK, Finn LD, Daliani D, Figg W, Ghaddar H, Gutterman JU. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin Cancer Res 7(5):1198-203, 5/2001. PMID: 11350884.
159. Millikan R, Baez L, Banerjee T, Wade J, Edwards K, Winn R, Smith TL, Logothetis C. Randomized phase 2 trial of ketoconazole and ketoconazole/doxorubicin in androgen independent prostate cancer. Urol Oncol 6(3):111-115, 5/2001. PMID: 11344001.
160. Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, Daliani D, Papandreou CN, Smith TL, Kim J, Podoloff DA, Logothetis CJ. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 357(9253):336-41, 2/2001. PMID: 11210994.
161. Schumacher G, Bruckheimer EM, Beham AW, Honda T, Brisbay S, Roth JA, Logothetis C, McDonnell TJ. Molecular determinants of cell death induction following adenovirus-mediated gene transfer of wild-type p53 in prostate cancer cells. Int J Cancer 91(2):159-66, 1/2001. PMID: 11146439.
162. Millikan, RE, Baez L, Banerjee T, Wade J, Edwards K, Winn R, Smith TL, Logothetis C. Randomized phase 2 trial of ketoconazole and ketoconazole /doxorubicin in androgen independent prostate cancer. Urologic Oncology 6(3):111-115, 2001.
163. Pagliaro L, Daliani D, Amato R, Tu SM, Jones D, Smith T, Logothetis C, Millikan R. A Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma. Cancer 89(3):615-8, 8/2000. PMID: 10931461.
164. Ozen M, Hopwood VL, Balbay MD, Johnston DA, Babaian RJ, Logothetis CJ, von Eschenbach AC, Pathak S. Correlation of non-random chromosomal aberrations in lymphocytes of prostate cancer patients with specific clinical parameters. Int J Oncol 17(1):113-7, 7/2000. PMID: 10853027.
165. Kim J, Palmer JL, Finn L, Hodges S, Bowes VV, Deftos L, Murphy G, Logothetis C. The pattern of serum markers in patients with androgen-independent adenocarcinoma of the prostate. Urol Oncol 5(3):97-103, 4/2000. PMID: 10765015.
166. Pettaway CA, Pisters LL, Troncoso P, Slaton J, Finn L, Kamoi K, Logothetis CJ. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J Clin Oncol 18(5):1050-7, 3/2000. PMID: 10694556.
167. Navone NM, Rodriquez-Vargas MC, Benedict WF, Troncoso P, McDonnell TJ, Zhou JH, Luthra R, Logothetis CJ. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer. Clin Cancer Res 6(3):1190-7, 3/2000. PMID: 10741751.
168. Lecrone V, Li W, Devoll RE, Logothetis C, Farach-Carson MC. Calcium signals in prostate cancer cells: specific activation by bone-matrix proteins. Cell Calcium 27(1):35-42, 2000. PMID: 10726209.
169. Amato RJ, Millikan R, Daliani D, Wood L, Logothetis C, Pollack A. Cyclophosphamide and carboplatin and selective consolidation in advanced seminoma. Clin Cancer Res 6(1):72-7, 2000. PMID: 10656434.
170. McCutcheon IE, Eng DY, Logothetis CJ. Brain metastasis from prostate carcinoma: antemortem recognition and outcome after treatment. Cancer 86(11):2301-11, 12/1999. PMID: 10590371.
171. Pisters LL, Pettaway CA, Hossan E, Evans R, Steiner MS, Wood CG, Troncoso P, McDonnell TJ, Fenstenmacher MJ, Logothetis CJ. Intraprostatic AD-p53 gene therapy followed by radical prostatectomy: feasibility and preliminary results. Prostate Cancer Prostatic Dis 2(S3):S27, 11/1999. PMID: 12496806.
172. Logothetis CJ. Introduction: a therapeutically relevant framework for the classification of human prostate cancer. Semin Oncol 26(4):369-74, 8/1999. PMID: 10482179.
173. Park DS, Prow DM, Amato RJ, Logothetis CJ. Management consideration in nonpulmonary visceral metastatic seminoma of testis. J Korean Med Sci 14(4):431-7, 8/1999. PMID: 10485624.
174. Luo W, Tapolsky M, Earley K, Wood CG, Wilson DR, Logothetis CJ, Lin SH. Tumor-suppressive activity of CD66a in prostate cancer. Cancer Gene Ther 6(4):313-21, 7/1999. PMID: 10419049.
175. Kim J, Logothetis CJ. Serologic tumor markers, clinical biology, and therapy of prostatic carcinoma. Urol Clin North Am 26(2):281-90, 5/1999. PMID: 10361551.
176. Park DS, Prow DM, Amato RJ, Ro JY, Logothetis CJ. Clinical characteristics of metachronous bilateral testicular tumors in the chemotherapeutic era. Yonsei Med J 40(2):137-43, 4/1999. PMID: 10333717.
177. Amato RJ, Bui C, Logothetis CJ. Estramustine in combination with vinblastine and mitomycin-C for patients with progressive androgen independent adenocarcinoma of the prostate. Prostate Cancer Prostatic Dis 2(2):83-87, 3/1999. PMID: 12496843.
178. Horti J, Dixon SC, Logothetis CJ, Guo Y, Reed E, Figg WD. Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitor. Br J Cancer 79(9):1588-93, 3/1999. PMID: 10188911.
179. Ozen M, Hopwood VL, Johnston DA, Babaian RJ, Logothetis CJ, von Eschenbach AC, Pathak S. Aneuploidy index in blood: a potential marker for early onset, androgen response, and metastasis in human prostate cancer. Urology 53(2):381-5, 2/1999. PMID: 9933059.
180. Czerniak B, Chaturvedi V, Li L, Hodges S, Johnston D, Roy JY, Luthra R, Logothetis C, Von Eschenbach AC, Grossman HB, Benedict WF, Batsakis JG. Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer. Oncogene 18(5):1185-96, 2/1999. PMID: 10022124.
181. Navone NM, Labate ME, Troncoso P, Pisters LL, Conti CJ, von Eschenbach AC, Logothetis CJ. p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. J Urol 161(1):304-8, 1999. PMID: 10037428.
182. Lin SH, Pu YS, Luo W, Wang Y, Logothetis CJ. Schedule-dependence of C-CAM1 adenovirus gene therapy in a prostate cancer model. Anticancer Res 19(1A):337-40, 1999. PMID: 10226564.
183. Herrmann JL, Briones F, Jr, Brisbay S, Logothetis CJ, McDonnell TJ. Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53. Oncogene 17(22):2889-99, 12/1998. PMID: 9879995.
184. Ozen M, Navone NM, Multani AS, Troncoso P, Logothetis CJ, Chung LW, von Eschenbach AC, Pathak S. Structural alterations of chromosome 5 in twelve human prostate cancer cell lines. Cancer Genet Cytogenet 106(2):105-9, 10/1998. PMID: 9797773.
185. Millikan RE, Logothetis CJ. Prospects for optimized clinical management of bladder cancer by application of phenotypic markers. J Natl Cancer Inst 90(14):1028-9, 7/1998. PMID: 9672249.
186. Logothetis CJ. Biologic foundation of the therapy for advanced germ cell tumors. Semin Urol Oncol 16(2):62-4, 5/1998. PMID: 9649228.
187. Tu SM, Pagliaro LC, Banks ME, Amato RJ, Millikan RE, Bugazia NA, Madden T, Newman RA, Logothetis CJ. Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer. Clin Cancer Res 4(5):1193-201, 5/1998. PMID: 9607577.
188. Corral, DA, Sella A, Pettaway CA, Amato RJ, Logothetis CJ, Ellerhorst J. Combination Chemotherapy for Metastatic or Locally Advanced Genitourinary Squamous Cell Carcinoma: A Phase II Study of Methotrexate, Cisplatin and Bleomycin (MPB) . Journal of Urology 160:1770-1774, 1998.
189. Moss, TJ, Logothetis CJ, Wood CG. Immunocytochemical (ICC) analysis: An attractive alternative to reverse transcriptase-polymerase chain reaction (RT-PCR) in molecular staging of prostate cancer (PCa). . J Urol 159(5):292, 1998.
190. Navone NM, Logothetis CJ, von Eschenbach AC, Troncoso P. Model systems of prostate cancer: uses and limitations. Cancer Metastasis Rev 17(4):361-71, 1998. PMID: 10453280.
191. Gjertsen BT, Logothetis CJ, McDonnell TJ. Molecular regulation of cell death and therapeutic strategies for cell death induction in prostate carcinoma. Cancer Metastasis Rev 17(4):345-51, 1998. PMID: 10453278.
192. Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu SM, Johnston D, Pollack A, Pathak S, von Eschenbach AC, Logothetis CJ. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res 3(12 Pt 1):2493-500, 12/1997. PMID: 9815652.
193. Ellerhorst JA, Sella A, Amato RJ, Tu SM, Millikan RE, Finn LD, Banks M, Logothetis CJ. Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. Cancer 80(11):2128-32, 12/1997. PMID: 9392335.
194. Ellerhorst JA, Tu SM, Amato RJ, Finn L, Millikan RE, Pagliaro LC, Jackson A, Logothetis CJ. Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res 3(12 Pt 1):2371-6, 12/1997. PMID: 9815636.
195. Millikan R, Logothetis C. Update of the NCCN guidelines for treatment of prostate cancer. Oncology (Williston Park) 11(11A):180-93, 11/1997. PMID: 9430189.
196. Hu SX, Ji W, Zhou Y, Logothetis C, Xu HJ. Development of an adenovirus vector with tetracycline-regulatable human tumor necrosis factor alpha gene expression. Cancer Res 57(16):3339-43, 8/1997. PMID: 9269991.
197. Chaturvedi V, Li L, Hodges S, Johnston D, Ro JY, Logothetis C, von Eschenbach AC, Batsakis JG, Czerniak B. Superimposed histologic and genetic mapping of chromosome 17 alterations in human urinary bladder neoplasia. Oncogene 14(17):2059-70, 5/1997. PMID: 9160886.
198. McDonnell TJ, Navone NM, Troncoso P, Pisters LL, Conti C, von Eschenbach AC, Brisbay S, Logothetis CJ. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J Urol 157(2):569-74, 2/1997. PMID: 8996359.
199. Corral DA, Logothetis CJ. New approaches in the treatment of metastatic transitional-cell cancer of the bladder. World J Urol 15(2):139-43, 1997. PMID: 9144905.
200. Sim SJ, Glassman AB, Ro JY, Lee JJ, Logothetis CJ, Liu FJ. Serum calcitonin in small cell carcinoma of the prostate. Ann Clin Lab Sci 26(6):487-95, 11/1996. PMID: 8908318.
201. Hutter RV, Montie JE, Busch C, Crignon DJ, Lieber M, Logothetis C, Ragde H, Reuter VE. Current prognostic factors and their relevance to staging. Cancer 78(2):369-71, 7/1996. PMID: 8674020.
202. Logothetis C, Swanson D, Amato R, Banks M, Finn L, Ayala A, Ro J, Babaian R, Dinney C, Ellerhorst J, Hall C, von Eschenbach A. Optimal delivery of perioperative chemotherapy: preliminary results of a randomized, prospective, comparative trial of preoperative and postoperative chemotherapy for invasive bladder carcinoma. J Urol 155(4):1241-5, 4/1996. PMID: 8632540.
203. Herrada J, Dieringer P, Logothetis CJ. Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal. J Urol 155(2):620-3, 2/1996. PMID: 8558675.
204. Tu, SM, Delpassand ES, Jones D, Finn L, Broussard WF, Amato RJ, Ellerhorst J, Kilbourn RG, Millikan RE, Logothetis CJ. A Phase I-II Study Combining Strontium-89 with Doxorubicin in the Treatment of Patients with Androgen-Independent Prostate Carcinoma. Urologic Oncology 2:191-197, 1996.
205. Amato, RJ, Ellerhorst J, Finn L, Logothetis CJ. Absence of anti-tumor activity with Prednisone in patients with progressive androgen-independent prostate carcinoma. Urologic Oncology 2:70-73, 1996.
206. Logothetis CJ. Chemotherapy for invasive and metastatic bladder cancer. . Advances in Oncology 12(1):19-22, 1996.
207. Hoosein, N, Abdul M, Logothetis CJ. Significance of neuroendocrine differentiation in prostatic carcinoma. The Cancer Journal 9(6):291-295, 1996.
208. Amato RJ, Ellerhorst J, Banks M, Logothetis CJ. Carboplatin and ifosfamide and selective consolidation in advanced seminoma. Eur J Cancer 31A(13):2223-8, 12/1995. PMID: 8652247.
209. Amato R, Meyers C, Ellerhorst J, Finn L, Kilbourn R, Sella A, Logothetis C. A phase I trial of intermittent high-dose alpha-interferon and dexamethasone in metastatic renal cell carcinoma. Ann Oncol 6(9):911-4, 11/1995. PMID: 8624294.
210. Tu SM, Hossan E, Amato R, Kilbourn R, Logothetis CJ. Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies. J Urol 154(5):1719-22, 11/1995. PMID: 7563331.
211. Logothetis CJ, Finn LD, Smith T, Kilbourn RG, Ellerhorst JA, Zukiwski AA, Sella A, Tu SM, Amato RJ. Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial. J Clin Oncol 13(9):2272-7, 9/1995. PMID: 7666085.
212. Hoosein NM, Martin KJ, Abdul M, Logothetis CJ, Kaddurah-Daouk R. Antiproliferative effects of cyclocreatine on human prostatic carcinoma cells. Anticancer Res 15(4):1339-42, 7/1995. PMID: 7654018.
213. Abdul M, Logothetis CJ, Hoosein NM. Growth-inhibitory effects of serotonin uptake inhibitors on human prostate carcinoma cell lines. J Urol 154(1):247-50, 7/1995. PMID: 7776439.
214. Sternberg CN, Raghaven D, Ohi Y, Bajorin D, Herr H, Kato T, Kuroda M, Logothetis CH, Scher H, Splinter TA. Neoadjuvant and adjuvant chemotherapy in advanced disease--what are the effects on survival and prognosis? Int J Urol 2(2):76-88, 6/1995. PMID: 7553308.
215. Kilbourn RG, Fonseca GA, Griffith OW, Ewer M, Price K, Striegel A, Jones E, Logothetis CJ. NG-methyl-L-arginine, an inhibitor of nitric oxide synthase, reverses interleukin-2-induced hypotension. Crit Care Med 23(6):1018-24, 6/1995. PMID: 7774211.
216. Daliani DD, Eisenberg PD, Weems J, Lord R, Fueger R, Logothetis CJ. The results of a phase II randomized trial comparing 5-fluorouracil and 5-fluorouracil plus alpha-interferon: observations on the design of clinical trials for androgen-independent prostate cancer. J Urol 153(5):1587-91, 5/1995. PMID: 7536271.
217. Fornage BD, Logothetis CJ, Swanson DA, Ro JY. Bilateral testicular metastases from prostate carcinoma: gray-scale and color Doppler sonographic findings. J Ultrasound Med 14(3):247-9, 3/1995. PMID: 7760471.
218. Tu, SM, Robinson ED, Amato RJ, Ellerhorst JA, Kilbourn RG, Logothetis CJ. A phase I study of FAP (5-Fluorouracil, -Interferon and Cisplatin) combined with Methotrexate for the treatment of advanced urothelial malignancies. Urologic Oncology 1:156-160, 1995.
219. Hoosein, N, Abdul M, McCabe R, Gero E, Deftos L, Banks M, Hodges S, Finn L, Logothetis CJ. Clinical significance of elevation in neuroendocrine factors and interleukin-6 in metastatic prostate cancer. Urologic Oncology 1:246-251, 1995.
220. Amato, RJ, Ellerhorst J, Sella A, Bui C, Zukiwski A, Logothetis CJ. Estramustine and vinblastine for patients with progressive androgen independent adenocarcinoma of the prostate. Urologic Oncology 1(4):168-172, 1995.
221. Hsieh, JT, Wu HC, Wang Y, Song WT, Li W, Finn L, Logothetis CJ. Evidence for the existence of an organ-specific androgen-independent pathway of progression in patients with metastatic prostate cancer. Urologic Oncology 1(2):67-72, 1995.
222. Nazario, A, Amato RJ, Hutchinson L, Bui C, Ellerhorst J, Logothetis CJ. Paclitaxel in extensively pretreated nonseminomatous germ cell tumors. Urologic Oncology 1:182-185, 1995.
223. Sella A, Aggarwal BB, Kilbourn RG, Bui CA, Zukiwski AA, Logothetis CJ. Phase I study of tumor necrosis factor plus actinomycin D in patients with androgen-independent prostate cancer. Cancer Biother 10(3):225-35, 1995. PMID: 8547961.
224. Abdul, M, Hsieh J-T, Logothetis CJ, Hoosein NM. Secretion of prostate-specific antigen-suppressing activity by two human prostate carcinoma cell lines. Urologic Oncology 1:38-41, 1995.
225. Logothetis CJ, Hossan EA, Smith TL. SMS 201-995 in the treatment of refractory prostatic carcinoma. Anticancer Res 14(6B):2731-4, 11/1994. PMID: 7872709.
226. Mitropoulos D, Dimopoulos MA, Kiroudi-Voulgari A, Zervas A, Dimopoulos C, Logothetis CJ. Neoadjuvant cisplatin and interferon-alpha 2B in the treatment and organ preservation of penile carcinoma. J Urol 152(4):1124-6, 10/1994. PMID: 8072080.
227. Logothetis CJ, Hoosein NM, Hsieh JT. The clinical and biological study of androgen independent prostate cancer (AI PCa). Semin Oncol 21(5):620-9, 10/1994. PMID: 7524155.
228. Crawford ED, Kozlowski JM, Debruyne FM, Fair WR, Logothetis CJ, Balmer C, Robinson RG, Porter AT, Kirk D. The use of strontium 89 for palliation of pain from bone metastases associated with hormone-refractory prostate cancer. Urology 44(4):481-5, 10/1994. PMID: 7524233.
229. Ellerhorst JA, Kilbourn RG, Amato RJ, Zukiwski AA, Jones E, Logothetis CJ. Phase II trial of low dose gamma-interferon in metastatic renal cell carcinoma. J Urol 152(3):841-5, 9/1994. PMID: 8051732.
230. Logothetis CJ, Hossan E, Recondo G, Sella A, Ellerhorst J, Kilbourn R, Zukiwski A, Amato R. 5-Fluorouracil and interferon-alpha in chemotherapy refractory bladder carcinoma: an effective regimen. Anticancer Res 14(3B):1265-9, 5/1994. PMID: 8067694.
231. Abdul M, Anezinis PE, Logothetis CJ, Hoosein NM. Growth inhibition of human prostatic carcinoma cell lines by serotonin antagonists. Anticancer Res 14(3A):1215-20, 5/1994. PMID: 8074475.
232. Sella A, Kilbourn R, Amato R, Bui C, Zukiwski AA, Ellerhorst J, Logothetis CJ. Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J Clin Oncol 12(4):683-8, 4/1994. PMID: 7512126.
233. Dimopoulos MA, Finn L, Logothetis CJ. Pattern of failure and survival of patients with metastatic urothelial tumors relapsing after cis-platinum-based chemotherapy. J Urol 151(3):598-600; discussion 600-1, 3/1994. PMID: 8308966.
234. Logothetis CJ. Chemotherapeutic approaches in advanced prostate cancer. . Oncology (Supplement) 8(11):15-18, 1994.
235. Sella A, Kilbourn RG, Gray I, Finn L, Zukiwski AA, Ellerhorst J, Amato RJ, Logothetis CJ. Phase I study of interleukin-2 combined with interferon-alpha and 5-fluorouracil in patients with metastatic renal cell cancer. Cancer Biother 9(2):103-11, 1994. PMID: 7812360.
236. Hoosein NM, Logothetis CJ, Chung LW. Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide and somatostatin analog RC-160 on the invasive capacity of human prostatic carcinoma cells. J Urol 149(5):1209-13, 5/1993. PMID: 8097794.
237. Dimopoulos MA, Logothetis CJ, Markowitz A, Sella A, Amato R, Ro J. Collecting duct carcinoma of the kidney. Br J Urol 71(4):388-91, 4/1993. PMID: 8499979.
238. Sella A, Swanson DA, Ro JY, Putnam JB, Jr, Amato RJ, Markowitz AB, Logothetis CJ. Surgery following response to interferon-alpha-based therapy for residual renal cell carcinoma. J Urol 149(1):19-21; discussion 21-2, 1993. PMID: 8417208.
239. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52(24):6940-4, 12/1992. PMID: 1458483.
240. Logothetis C. Treatment of chemotherapy-refractory metastatic urothelial tumors. Urol Clin North Am 19(4):775-7, 11/1992. PMID: 1441031.
241. Logothetis CJ, Xu HJ, Ro JY, Hu SX, Sahin A, Ordonez N, Benedict WF. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J Natl Cancer Inst 84(16):1256-61, 8/1992. PMID: 1640485.
242. Amato RJ, Logothetis CJ, Hallinan R, Ro JY, Sella A, Dexeus FH. Chemotherapy for small cell carcinoma of prostatic origin. J Urol 147(3):935-7, 3/1992. PMID: 1311396.
243. Giralt SA, Dexeus F, Amato R, Sella A, Logothetis C. Hyperthyroidism in men with germ cell tumors and high levels of beta-human chorionic gonadotropin. Cancer 69(5):1286-90, 3/1992. PMID: 1371235.
244. Sella A, Logothetis CJ, Fitz K, Dexeus FH, Amato R, Kilbourn R, Wallace S. Phase II study of interferon-alpha and chemotherapy (5-fluorouracil and mitomycin C) in metastatic renal cell cancer. J Urol 147(3):573-7, 3/1992. PMID: 1538431.
245. Grignon DJ, Ro JY, Ayala AG, Shum DT, Ordonez NG, Logothetis CJ, Johnson DE, Mackay B. Small cell carcinoma of the urinary bladder. A clinicopathologic analysis of 22 cases. Cancer 69(2):527-36, 1/1992. PMID: 1309435.
246. Logothetis CJ. Chemotherapy resistant transitional cell carcinoma as a target for chemoprevention. J Cell Biochem Suppl 16I:128-31, 1992. PMID: 1305675.
247. Chung LW, Li W, Gleave ME, Hsieh JT, Wu HC, Sikes RA, Zhau HE, Bandyk MG, Logothetis CJ, Rubin JS, et al. Human prostate cancer model: roles of growth factors and extracellular matrices. J Cell Biochem Suppl 16H:99-105, 1992. PMID: 1289680.
248. Sella, A, Amato RJ, Fitz K, Kilbourn RG, Logothetis, CJ. Interferon-alpha and 5-fluorouracil Combination Chemotherapy for Metastatic Renal Cell Cancer. Inter and Cyto 20, 1992.
249. Wishnow KI, Levinson AK, Johnson DE, Tenney DM, Grignon DJ, Ro JY, Ayala AJ, Logothetis CJ, Swanson DA, Babaian RJ, et al. Stage B (P2/3A/N0) transitional cell carcinoma of bladder highly curable by radical cystectomy. Urology 39(1):12-6, 1992. PMID: 1728789.
250. Logothetis C, Hoosein N. The inhibition of the paracrine progression of prostate cancer as an approach to early therapy of prostatic carcinoma. J Cell Biochem Suppl 16H:128-34, 1992. PMID: 1337763.
251. Dexeus FH, Logothetis CJ, Sella A, Amato R, Kilbourn R, Fitz K, Striegel A. Combination chemotherapy with methotrexate, bleomycin and cisplatin for advanced squamous cell carcinoma of the male genital tract. J Urol 146(5):1284-7, 11/1991. PMID: 1719241.
252. Sella A, el Naggar A, Ro JY, Dexeus FH, Amato RJ, Lee JS, Finn L, Logothetis CJ. Evidence of malignant features in histologically mature teratoma. J Urol 146(4):1025-8, 10/1991. PMID: 1680200.
253. Dimopoulos MA, Amato RJ, Logothetis CJ. Predictive factors for effective salvage therapy of nonseminomatous germ cell tumors of testis. Urology 38(4):351-4, 10/1991. PMID: 1661457.
254. Dexeus FH, Logothetis CJ, Sella A, Amato R, Kilbourn R, Ogden S, Striegel A, Kwan J, Newman RA. Circadian infusion of floxuridine in patients with metastatic renal cell carcinoma. J Urol 146(3):709-13, 9/1991. PMID: 1831513.
255. Logothetis CJ. Organ preservation in bladder carcinoma: a matter of selection. J Clin Oncol 9(9):1525-6, 9/1991. PMID: 1875215.
256. Dexeus FH, Logothetis CJ, Sella A, Fitz K, Striegel A, Amato RJ, Liu FJ. Serum biomarkers in metastatic renal cell carcinoma. Urology 38(1):6-10, 7/1991. PMID: 1714107.
257. Sella A, Logothetis CJ, Dexeus FH, Amato R, Finn L, Fitz K. Cisplatin combination chemotherapy for elderly patients with urothelial tumours. Br J Urol 67(6):603-7, 6/1991. PMID: 2070205.
258. Dexeus FH, Kilbourn R, Chong C, Logothetis CJ, Sella A, Grignon D. Association of germ cell tumors and Hodgkin's disease. Urology 37(2):129-34, 2/1991. PMID: 1846990.
259. Logothetis CJ, Hossan E, Sella A, Dexeus FH, Amato RJ. Fluorouracil and recombinant human interferon alfa-2a in the treatment of metastatic chemotherapy-refractory urothelial tumors. J Natl Cancer Inst 83(4):285-8, 2/1991. PMID: 1994058.
260. Sella A, Logothetis CJ, Dexeus FH, Amato R. Chemotherapy immediately after surgery for patients with germ cell tumors. Urology 36(3):264-6, 9/1990. PMID: 2168105.
261. Gutterman J, Vadhan-Raj S, Logothetis C, Anaissle E, Estey E, Talpaz M, Kurzrock R. Effects of granulocyte-macrophage colony-stimulating factor in iatrogenic myelosuppression, bone marrow failure, and regulation of host defense. Semin Hematol 27(3):15-24, 7/1990. PMID: 2198660.
262. Logothetis CJ, Dexeus FH, Finn L, Sella A, Amato RJ, Ayala AG, Kilbourn RG. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8(6):1050-5, 6/1990. PMID: 2189954.
263. Logothetis CJ, Dexeus FH, Sella A, Amato RJ, Kilbourn RG, Finn L, Gutterman JU. Escalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated recombinant human granulocyte-macrophage colony-stimulating factor. J Natl Cancer Inst 82(8):667-72, 4/1990. PMID: 2181151.
264. Dexeus FH, Logothetis CJ, Sella A, Fitz K, Amato R, Reuben JM, Dozier N. Phase II study of coumarin and cimetidine in patients with metastatic renal cell carcinoma. J Clin Oncol 8(2):325-9, 2/1990. PMID: 2137163.
265. Logothetis CJ. The case for relevant staging of germ cell tumors. Cancer 65(3):709-17, 2/1990. PMID: 2154316.
266. Logothetis CJ, Chong C, Dexeus FH, Sella A, Ogden S. Intensive chemotherapy for metastatic nonseminomatous germ cell tumors. Prog Clin Biol Res 350:301-7, 1990. PMID: 1696741.
267. Logothetis CJ, Dexeus FH, Chong C, Sella A, Ogden S. The impact of chemotherapy on the survival of patients with metastatic urothelial tumors. Prog Clin Biol Res 350:107-14, 1990. PMID: 2201037.
268. Dexeus FH, Logothetis CJ, Sella A, Finn L. Interferon alternating with chemotherapy for patients with metastatic renal cell carcinoma. Am J Clin Oncol 12(4):350-4, 8/1989. PMID: 2667326.
269. Sella A, Dexeus FH, Chong C, Ro JY, Logothetis CJ. Radiation therapy-associated invasive bladder tumors. Urology 33(3):185-8, 3/1989. PMID: 2919477.
270. Tetu B, Ro JY, Ayala AG, Ordonez NG, Logothetis CJ, von Eschenbach AC. Small cell carcinoma of prostate associated with myasthenic (Eaton-Lambert) syndrome. Urology 33(2):148-52, 2/1989. PMID: 2536972.
271. Logothetis CJ, Dexeus FH, Chong C, Sella A, Ayala AG, Ro JY, Pilat S. Cisplatin, cyclophosphamide and doxorubicin chemotherapy for unresectable urothelial tumors: the M.D. Anderson experience. J Urol 141(1):33-7, 1989. PMID: 2908950.
272. Dexeus FH, Shirkhoda A, Logothetis CJ, Chong C, Sella A, Ogden S, Swanson D. Clinical and radiological correlation of retroperitoneal metastasis from nonseminomatous testicular cancer treated with chemotherapy. Eur J Cancer Clin Oncol 25(1):35-43, 1989. PMID: 2920767.
273. Logothetis CJ. The role of chemotherapy in the management of urothelial tumors: Interpretation of the M. D. Anderson Cancer Center results. . World Journal of Urology 6(3):163-166, 12/1988.
274. Logothetis CJ, Johnson DE, Chong C, Dexeus FH, Sella A, Ogden S, Smith T, Swanson DA, Babaian RJ, Wishnow KI, et al. Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update. J Clin Oncol 6(10):1590-6, 10/1988. PMID: 3171626.
275. Shirkhoda A, Dexeus FH, Logothetis CJ. Clinical and radiologic staging of locally advanced and inoperable bladder carcinoma. J Comput Tomogr 12(4):298-302, 10/1988. PMID: 3197433.
276. Dunphy CH, Ayala AG, Swanson DA, Ro JY, Logothetis C. Clinical stage I nonseminomatous and mixed germ cell tumors of the testis. A clinicopathologic study of 93 patients on a surveillance protocol after orchiectomy alone. Cancer 62(6):1202-6, 9/1988. PMID: 2842034.
277. Chong CD, Logothetis CJ, Savaraj N, Fritsche HA, Gietner AM, Samuels ML. The correlation of vinblastine pharmacokinetics to toxicity in testicular cancer patients. J Clin Pharmacol 28(8):714-8, 8/1988. PMID: 3216038.
278. Dexeus FH, Logothetis CJ, Chong C, Sella A, Ogden S. Genetic abnormalities in men with germ cell tumors. J Urol 140(1):80-4, 7/1988. PMID: 2837589.
279. Logothetis CJ, Johnson DE, Chong C, Dexeus FH, Ogden S, von Eschenbach A, Ayala A. Adjuvant chemotherapy of bladder cancer: a preliminary report. J Urol 139(6):1207-11, 6/1988. PMID: 3373589.
280. Chong CD, Logothetis CJ, von Eschenbach AC, Ayala AG, Samuels ML. Successful treatment of pure endodermal sinus tumors in adult men. J Clin Oncol 6(2):303-7, 2/1988. PMID: 2448426.
281. Floyd C, Ayala AG, Logothetis CJ, Silva EG. Spermatocytic seminoma with associated sarcoma of the testis. Cancer 61(2):409-14, 1/1988. PMID: 3334976.
282. Logothetis CJ, Samuels ML, Ogden SL, Dexeus FH, Chong CD. Cyclophosphamide and sequential cisplatin for advanced seminoma: long-term followup in 52 patients. J Urol 138(4):789-94, 10/1987. PMID: 3656535.
283. Sella A, Logothetis CJ, Ro JY, Swanson DA, Samuels ML. Sarcomatoid renal cell carcinoma. A treatable entity. Cancer 60(6):1313-8, 9/1987. PMID: 2441841.
284. Logothetis CJ, Swanson DA, Dexeus F, Chong C, Ogden S, Ayala AG, von Eschenbach AC, Johnson DE, Samuels ML. Primary chemotherapy for clinical stage II nonseminomatous germ cell tumors of the testis: a follow-up of 50 patients. J Clin Oncol 5(6):906-11, 6/1987. PMID: 2438389.
285. Tetu B, Ro JY, Ayala AG, Johnson DE, Logothetis CJ, Ordonez NG. Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases. Cancer 59(10):1803-9, 5/1987. PMID: 3030528.
286. Dexeus FH, Logothetis CJ, Samuels ML, Ayala AG, Hossan E. Complete responses in metastatic transitional cell carcinoma of the prostate with cisplatin regimens. J Urol 137(1):122-5, 1987. PMID: 3795354.
287. Chong C, Logothetis CJ, von Eschenbach A, Ayala A, Samuels M. Orchiectomy in advanced germ cell cancer following intensive chemotherapy: a comparison of systemic to testicular response. J Urol 136(6):1221-3, 12/1986. PMID: 3022018.
288. Dexeus FH, Logothetis C, Samuels ML, Hossan B. Phase II study of spirogermanium in metastatic prostate cancer. Cancer Treat Rep 70(9):1129-30, 9/1986. PMID: 3742495.
289. Dexeus F, Logothetis C, Hossan E, Samuels ML. Carcinoembryonic antigen and beta-human chorionic gonadotropin as serum markers for advanced urothelial malignancies. J Urol 136(2):403-7, 8/1986. PMID: 2426474.
290. Logothetis CJ, Samuels ML, Selig DE, Ogden S, Dexeus F, Swanson D, Johnson D, von Eschenbach A. Cyclic chemotherapy with cyclophosphamide, doxorubicin, and cisplatin plus vinblastine and bleomycin in advanced germinal tumors. Results with 100 patients. Am J Med 81(2):219-28, 8/1986. PMID: 2426944.
291. Logothetis CJ, Samuels ML, Selig DE, Johnson DE, Swanson DA, von Eschenbach AC. Primary chemotherapy followed by a selective retroperitoneal lymphadenectomy in the management of clinical stage II testicular carcinoma: a preliminary report. J Urol 134(6):1127-30, 12/1985. PMID: 2414470.
292. Logothetis CJ, Samuels ML, Ogden S. Chemotherapy for adenocarcinomas of bladder and urachal origin: 5-fluorouracil, doxorubicin, and mitomycin-C. Urology 26(3):252-5, 9/1985. PMID: 3929441.
293. Logothetis CJ, Samuels ML, Ogden S, Dexeus FH, Swanson D, Johnson DE, von Eschenbach A. Cyclophosphamide, doxorubicin and cisplatin chemotherapy for patients with locally advanced urothelial tumors with or without nodal metastases. J Urol 134(3):460-4, 9/1985. PMID: 2993671.
294. Dexeus F, Logothetis CJ, Samuels ML, Hossan E, von Eschenbach AC. Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer. Cancer Treat Rep 69(7-8):885-6, 7/1985. PMID: 4016795.
295. Logothetis CJ, Samuels ML, Selig DE, Dexeus FH, Johnson DE, Swanson DA, von Eschenbach AC. Chemotherapy of extragonadal germ cell tumors. J Clin Oncol 3(3):316-25, 3/1985. PMID: 2579212.
296. Logothetis CJ, Samuels ML, Selig D, Swanson D, Johnson DE, von Eschenbach AC. Improved survival with cyclic chemotherapy for nonseminomatous germ cell tumors of the testis. J Clin Oncol 3(3):326-35, 3/1985. PMID: 2579213.
297. Logothetis CJ, Newell GR, Samuels ML. Testicular cancer in homosexual men with cellular immune deficiency: report of 2 cases. J Urol 133(3):484-6, 3/1985. PMID: 2579253.
298. Logothetis CJ, Samuels ML, Selig DE, Wallace S, Johnson DE. Combined intravenous and intra-arterial cyclophosphamide, doxorubicin, and cisplatin (CISCA) in the management of select patients with invasive urothelial tumors. Cancer Treat Rep 69(1):33-8, 1985. PMID: 2981619.
299. Logothetis CJ. Perioperative chemotherapy for the management of primary local regional urothelial tumors. Prog Clin Biol Res 201:359-66, 1985. PMID: 3841594.
300. Logothetis CJ. Preoperative chemotherapy in the treatment of germinal tumors. Prog Clin Biol Res 201:341-50, 1985. PMID: 2419920.
301. Rusch VW, Logothetis C, Samuels M. Endodermal sinus tumor of the mediastinum. Report of apparent cure in two patients with extensive disease. Chest 86(5):745-7, 11/1984. PMID: 6207993.
302. Logothetis CJ. Choriocarcinoma syndrome. . Cancer Bulletin 36(2):118-120, 3/1984.
303. Logothetis CJ, Samuels ML. Surgery in the management of stage III germinal cell tumors. Observations on the M.D. Anderson Hospital experience, 1971-1979. Cancer Treat Rev 11(1):27-37, 3/1984. PMID: 6203643.
304. Logothetis CJ, Samuels M. Intra-arterial chemotherapy for malignant urothelial tumors. . Cancer Bulletin 36(1):47-52, 1984.
305. Logothetis CJ. The lymphoma that wasn’t. . World Journal of Urology 2:73-75, 1984.
306. Logothetis CJ, Samuels ML, Trindade A, Grant C, Gomez L, Ayala A. The prognostic significance of endodermal sinus tumor histology among patients treated for stage III nonseminomatous germ cell tumors of the testes. Cancer 53(1):122-8, 1984. PMID: 6317156.
307. Logothetis CJ, Samuels ML, von Eschenbach AC, Trindade A, Ogden S, Grant C, Johnson DE. Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. J Clin Oncol 1(6):368-79, 6/1983. PMID: 6422006.
308. Libshitz HI, Jing BS, Wallace S, Logothetis CJ. Sterilized metastases: a diagnostic and therapeutic dilemma. AJR Am J Roentgenol 140(1):15-9, 1983. PMID: 6600307.
309. Bracken RB, Johnson DE, Frazier OH, Logothetis CJ, Trindade A, Samuels ML. The role of surgery following chemotherapy in stage III germ cell neoplasms. J Urol 129(1):39-43, 1983. PMID: 6298475.
310. Logothetis CJ, Samuels ML, Trindade A, Johnson DE. The growing teratoma syndrome. Cancer 50(8):1629-35, 10/1982. PMID: 6288220.
311. Logothetis CJ, Samuels ML, Wallace S, Chuang V, Trindade A, Grant C, Haynie TP, 3rd, Johnson DE. Management of pelvic complications of malignant urothelial tumors with combined intra-arterial and iv chemotherapy. Cancer Treat Rep 66(7):1501-7, 7/1982. PMID: 7046931.
312. Logothetis, CJ, von Eschenbach A, Samuels ML, Trindade A, Johnson DE. DMF regimen for hormone-refractory adenocarcinoma of the prostate - The first 42 patients. Cancer Bulletin 34(1):26-28, 1982.
313. Logothetis CJ, von Eschenbach AC, Samuels ML, Trindade A, Johnson DE. Doxorubicin, mitomycin, and 5-FU (DMF) in the treatment of hormone-resistant stage D prostate cancer: a preliminary report. Cancer Treat Rep 66(1):57-63, 1982. PMID: 7053267.
314. Logothetis CJ, Samuels ML, Trindade A. The management of brain metastases in germ cell tumors. Cancer 49(1):12-8, 1982. PMID: 6274499.
315. Trindade A, Samuels ML, Logothetis CJ. Chemotherapy of carcinoma of renal pelvis: preliminary report. Urology 18(1):54-9, 7/1981. PMID: 6894814.
316. Logothetis CJ. CISCA Chemotherapy for bladder cancer. Cancer Bulletin 33(2):79-80, 3/1981.

Invited Articles

1. Logothetis CJ. The case for a biologically based classification of prostate cancer. Semin Oncol 30(5):562-6, 10/2003. PMID: 14571406.
2. Logothetis C, Millikan R. Docetaxel in the management of advanced or metastatic urothelial tract cancer. Oncology (Williston Park) 16(6 Suppl 6):107-11, 6/2002. PMID: 12108893.
3. Logothetis CJ. A Framework for Rational and Accelerated Development of Therapy for Prostate Cancer. . Principles and Practice of Oncology 16(6), 2002.
4. Logothetis CJ. Docetaxel in the Treatment of Prostate Cancer: Opportunities for Combination Regimens and Challenges to Development. . Seminars in Oncology 28(4):Supplement N, 2001.
5. Bahnson RR, Hanks GE, Huben RP, Kantoff P, Kozlowski JM, Kuettel M, Lange PH, Logothetis C, Pow-Sang JM, Roach M, 3rd, Sandler H, Scardino PT, Taylor RJ, Urban DA, Walsh PC, Wilson TG. NCCN Practice Guidelines for Prostate Cancer. Oncology (Williston Park) 14(11A):111-9, 11/2000. PMID: 11195405.
6. Baker LH, Hanks G, Gershenson D, Kantoff P, Lange P, Logothetis C, Sandler H, Walsh P. NCCN Prostate Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park) 10(11 Suppl):265-88, 11/1996. PMID: 8953609.

Editorials

1. Logothetis CJ, Millikan R. Chemotherapy for advanced prostate cancer: 25 years later. J Clin Oncol 26(15):2423-4, 5/2008. PMID: 18487561.
Other Articles
1. Logothetis CJ. Prostate cancer bone metastases: not so systemic after all. Lancet Oncol 15(7):675-6, 6/2014. e-Pub 5/2014. PMID: 24836275.
2. Logothetis CJ. Treatment of castrate-resistant prostate cancer. J Urol 190(2):439-40, 8/2013. e-Pub 5/2013. PMID: 23707438.
3. Logothetis CJ. Treatment of prostate cancer metastases: more than semantics. Lancet 379(9810):4-6, 1/2012. e-Pub 11/2011. PMID: 22093188.
4. Logothetis CJ, Siefker-Radtke A. Words of wisdom. Re: final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. Eur Urol 57(4):728-9, 4/2010. PMID: 20965043.
5. Logothetis CJ, Schellhammer PF. High-grade prostate cancer and the prostate cancer prevention trial. Cancer Prev Res (Phila Pa) 1(3):151-2, 5/2008. PMID: 19138948.
6. Tu, S, Jones D, Finn L, Amato R, Ellerhorst J, Kilbourn R, Logothetis CJ. Strontium-89 (Str-89) combined with adriamycin (Adr) in the treatment of patients (pts) with androgen-independent prostate carcinoma (AI PCa), 6/1995.
7. Logothetis CJ, Amato RJ. Management of Residual Mass Following Effective Therapy for Seminoma, 3/1993.

Abstracts

1. Jian Gu, Yonggang He, Sara S. Strom, Christopher J. Logothetis, Jeri Kim, Xifeng Wu. A genetic variant near KLK3 gene is associated with aggressive prostate cancer and can stratify Gleason score 7 patients. AACR (#5547), 2014.
2. Eleonora Dondossola, Stephanie Alexander, Steve Alexander, Boris M. Holzapfel, Christopher J. Logothetis, Dietmar W. Hutmacher, Peter Fried. A humanized bone model for preclinical monitoring of prostate cancer lesions by intravital multiphoton microscopy. AACR (#4941), 2014.
3. Paul Gettys Corn, Shi-Ming Tu, Amado J. Zurita, John C. Araujo, Lance C. Pagliaro, Christopher Logothetis, Ana Aparicio. A randomized phase I/II study to examine the contribution of carboplatin to cabazitaxel for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) with and without anaplastic features. Genitourinary Cancers Symposium (#148), 2014.
4. Evan Y. Yu, Fred Saad, Anil Londhe, Neal D. Shore, Hendrik Van Poppel, Dana E. Rathkopf, Matthew R. Smith, Christopher Logothetis, Paul L. De Souza, Karim Fizazi, Peter F.A. Mulders, Paul N. Mainwaring, John D. Hainsworth, Tomasz M. Beer, Scott A. North, Eric Jay Small, Howard I. Scher, Thomas W. Griffin, Margaret K. Yu, Charles J. Ryan. Association of alkaline phosphatase (ALP) with clinical outcomes in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302. Genitourinary Cancers Symposium (#27), 2014.
5. Patricia A. Parker, John W. Davis, David Latini, George Baum, Xuemei Wang, John Francis Ward, Deborah A. Kuban, Steven J. Frank, Andrew Lee, Christopher Logothetis, Jeri Kim. Associations between uncertainty, anxiety, and quality of life in men with favorable-risk prostate cancer on active surveillance: Two-and-a-half years' follow-up. Genitourinary Cancers Symposium (#135), 2014.
6. Tomasz M. Beer, Christopher Logothetis, Winald R. Gerritsen, Eugene D. Kwon, Howard I. Scher, Alberto Bossi, Alfons JM van den Eertwegh, Charles G. Drake, Brent McHenry, David Liu, Karim Fizazi. Characterization of immune-related adverse events (irAEs) in a phase 3 trial of ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel mCRPC. Genitourinary Cancers Symposium (#52), 2014.
7. Shore, Neal (Myrtle Beach, SC); Rathkopf, Dana; Smith, Matthew R.; de Bono, Johann S.; Logothetis, Christopher; de Souza, Paul; Fizazi, Karim; Mulders, Peter F.A.; Mainwaring, Paul; Hainsworth, John D.; Beer, Tomasz M.; North, Scott; Fradet, Yves; Griffin, Thomas; Park, Youn C.; Kheoh, Thian; Small, Eric J.; Scher, Howard I.; Molina, Arturo; Ryan, Charles J. Efficacy and Long-term Safety Analysis of Study COU-AA-302: Abiraterone Acetate Plus Prednisone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer. AUA (#PD27-01), 2014.
8. Eleni Efstathiou, Mark Anton Titus, Sijin Wen, Aileen SanMiguel, Anh Hoang, Angela De Haas-Amatsaleh, Frank Perabo, De Phung, Patricia Troncoso, Taoufik Ouatas, Christopher Logothetis. Enzalutamide (ENZA) in combination with abiraterone acetate (AA) in bone metastatic castration resistant prostate cancer (mCRPC). ASCO (#5000), 2014.
9. Shi-Ming Tu, Mehmet Asim Bilen, Zachary H. Tu, Raphael General, John Francis Ward, Louis L. Pisters, Rosale General, Adrienne H. Chen, Yago Nieto, Lance C. Pagliaro, S. J. Yeung, Christopher Logothetis, Sue-Hwa Lin, Ivan Gorlov. Nonseminomatous germ cell tumor of the testis: Prognostic factors for a lethal phenotype. Genitourinary Cancers Symposium (#390), 2014.
10. Yohann Loriot, Lance C. Pagliaro, Aude Flechon, Jozef Mardiak, Lionnel Geoffrois, Pierre Kerbrat, Christine Chevreau, Remy Delva, Frederic Rolland, Christine Theodore, Binh Bui, Gwenaelle Gravis, Jean-Christophe Eymard, Jean-pierre Malhaire, Claude Linassier, Muriel Habibian, Christopher Logothetis, Stephane Culine, Agnes Laplanche, Karim Fizazi. Patterns of relapse in poor-prognosis germ cell tumors in the GETUG 13 trial: Implications for assessment of brain progression. Genitourinary Cancers Symposium (#365), 2014.
11. Sankar Narayan Maity, Guanglin Wu, Jing-Fang Lu, Anh Hoang, Yosef Landesman, Dilara McCauley, Sharon Shacham, Michael G. Kauffman, Ana M. Aparicio, Eleni Efstathiou, John C. Araujo, Christopher J. Logothetis. Preclinical efficacy of the novel, oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) on castration resistant prostate cancer. AACR (#3808), 2014.
12. Deborah Sokol Ricci, Weimin Li, Thomas W. Griffin, Michael Gormley, Erin Henitz, Charles J. Ryan, Johann Sebastian De Bono, Gerhardt Attard, Alfons JM van den Eertwegh, Dirk L. Schrijvers, John J. Gullo, Henrik Suttmann, Joan Carles, Jose Maria Piulats Rodriguez, Robert J. Jones, Christopher Logothetis, Dana E. Rathkopf, Howard I. Scher, Eleni Efstathiou. Predicting response to abiraterone acetate (AA): mRNA biomarker analysis of study COU-AA-302. ASCO (#5058), 2014.
13. Charles G. Drake, Eugene D. Kwon, Karim Fizazi, Alberto Bossi, Alfons JM van den Eertwegh, Christopher Logothetis, Howard I. Scher, Tomasz M. Beer, Brent McHenry, David Liu, Winald R. Gerritsen. Results of subset analyses on overall survival (OS) from study CA184-043: Ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel metastatic castration-resistant prostate cancer (mCRPC). Genitourinary Cancers Symposium (#02), 2014.
14. Mehmet Asim Bilen, Kenneth R. Hess, Ana Aparicio, Jeri Kim, Amado J. Zurita, Lance C. Pagliaro, John C. Araujo, Paul Gettys Corn, Bradley J. Atkinson, Nizar M. Tannir, Padmanee Sharma, Sue-Hwa Lin, Christopher Logothetis, Shi-Ming Tu. Sipuleucel-T cellular immunotherapy: Clinical predictors of survival in patients with castration-resistant prostate cancer (CRPC). ASCO (#e16046), 2014.
15. William R. Moore, Sankar N. Maity, Joel Robert Eisner, Edward P. Garvey, William J. Hoekstra, Mark Anton Titus, Christopher Logothetis, John C. Araujo, Eleni Efstathiou, Robert J. Schotzinger. The enzymology of the selective CYP17 lyase inhibitor, VT-464, and its effects in castration-resistant prostate cancer (CRPC) models. Genitourinary Cancers Symposium (#158), 2014.
16. Jeri Kim, John W. Davis, Eric A. Klein, Cristina Magi-Galluzzi, Yair Lotan, John F. Ward, Louis L. Pisters, Joseph W. Basler, Curtis A. Pettaway, Elsa M. Li Ning Tapia, Xuemei Wang, Kim-Anh Do, Jack Lee, Lana A. Vornik, Joe Tangrea, Howard L. Parnes, Scott M. Lippman, Ian M. Thompson, Powel H. Brown, Patricia Troncoso, Christopher J. Logothetis. A double-blind randomized controlled multisite trial evaluating tissue effects of preoperative finasteride in clinically organ-confined prostate cancer: Pathologic outcomes. AACR (#LB-195), 2013.
17. Ana M. Aparicio, Sankar Maity, Xuemei Wang, Anh G. Hoang, Eleni Efstathiou, Patricia Troncoso, Christopher J. Logothetis. A molecular characterization of the anaplastic prostate carcinomas. AACR (#1195), 2013.
18. Karim Fizazi, Lance C. Pagliaro, Aude Flechon, Jozef Mardiak, Lionnel Geoffrois, Pierre Kerbrat, Christine Chevreau, Remy Delva, Frederic Rolland, Christine Theodore, Guilhem Roubaud, Gwenaelle Gravis, Jean-Christophe Eymard, Jean-pierre Malhaire, Claude Linassier, Muriel Habibian, Florence Journeau, Christopher Logothetis, Stephane Culine, Agnes Laplanche. A phase III trial of personalized chemotherapy based on serum tumor marker decline in poor-prognosis germ-cell tumors: Results of GETUG 13. ASCO (#LBA4500), 2013.
19. Fred Saad; Neal D Shore; Hendrik Van Poppel; Dana Rathkopf; Matthew R. Smith; Johann S. de Bono; Christopher Logothetis; Paul de Souza; Karim Fizazi; Peter FA Mulders; Paul Mainwaring; John D Hainsworth; Tomasz M Beer; Scott North; Yves Fradet; Tom Griffin; Thian Kheoh; Eric J Small; Howard I Scher; Arturo Molina; Charles J Ryan. Abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy – Interim analysis of the COU-AA-302 phase 3 trial. AUA (#713), 2013.
20. Howard I. Scher, Matthew R. Smith, Christopher Sweeney, Paul Gettys Corn, Christopher Logothetis, Nicholas J. Vogelzang, David C. Smith, Maha Hussain, Daniel J. George, Johann Sebastian De Bono, Celestia S. Higano, Eric Jay Small, Jonathan Goldin, Matthew S. Brown, Dana T. Aftab, Mojtaba Noursalehi, Aaron Weitzman, Ethan M. Basch; Memorial Sloan-Kettering Cancer Center, New York, NY; Massachusetts General Hospital Cancer Center, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; The University of Texas MD Anderson Cancer Center, Houston, TX; Comprehensive Cancer Centers of Nevada, The US Oncology Network, Las Vegas, NV; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Duke Cancer Institute, Durham, NC; The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California, San Francisco, San Francisco, CA; University of California, Los Angeles, Los Angeles, CA; Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, CA; Exelixis, Inc, South San Francisco, CA. An exploratory analysis of bone scan lesion area (BSLA), circulating tumor cell (CTC) change, pain reduction, and overall survival (OS) in patients (pts) with castration-resistant prostate cancer (CRPC) treated with cabozantinib (cabo): Updated results of a phase II nonrandomized expansion (NRE) cohort. ASCO (#5026), 2013.
21. Tomasz M. Beer, Christopher Logothetis, Padmanee Sharma, Yohann Loriot, Karim Fizazi, Alberto Bossi, Eugene D. Kwon, Brent McHenry, Paul Gagnier, Winald R. Gerritsen; Oregon Health & Science University Knight Cancer Institute, Portland, OR; The University of Texas MD Anderson Cancer Center, Houston, TX; Institut Gustave Roussy, Villejuif, France; Mayo Clinic, Rochester, MN; Bristol-Myers Squibb, Wallingford, CT; Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands. CA184-095: A randomized, double-blind, phase III trial to compare the efficacy of ipilimumab (Ipi) versus placebo in asymptomatic or minimally symptomatic patients (pts) with metastatic chemotherapy-naive castration-resistant prostate cancer (CRPC). ASCO (#TPS5093), 2013.
22. Amado J. Zurita, Farideh Z. Bischoff, Ivan Gorlov, Julie Ann Mayer, Tony J. Pircher, Steve Mikolajczyk, Christopher Logothetis, Sue-Hwa Lin; The University of Texas MD Anderson Cancer Center, Houston, TX; Biocept Inc., San Diego, CA. Cadherin-11 (Cad11) for detection of epithelial-mesenchymal transition (EMT) in circulating prostate cancer (PCa) cells. ASCO (#e22047), 2013.
23. Ana M. Aparicio, Emily Gallichotte, Heather Cheng, Suk-Young Yoo, Sankar Maity, Christopher Logothetis, Muneesh Tewari. Circulating micro-RNAs can detect adaptive response to therapy and aggressive subset of prostate cancer. AACR (#1205), 2013.
24. Jerome P. Richie; Robert B. Montgomery; Christopher J. Logothetis; Glenn J. Bubley; Bruce L. Dalkin; Martin G. Sanda; Massimo F. Loda; Rosina T. Lis; Lawrence D. True; Patricia Troncoso; Elizabeth M. Genega; Steven P. Balk; Elahe A. Mostaghel; Trevor M. Penning; Peter S. Nelson; Wanling Xie; Christopher M. Haqq; NamPhuong Tran; Weimin Peng; Daniel Tamae; Thian Kheoh; Arturo Molina; Philip W. Kantoff; Mary-Ellen Taplin. Effect of Neoadjuvant Abiraterone Acetate Plus Leuprolide Acetate on PSA, Pathologic Response, and Intraprostatic/Serum Androgen Levels in Localized High-Risk Prostate Cancer: Results of a Randomized Phase 2 Study. AUA (#665), 2013.
25. Sankar N. Maity, Guanglin Wu, Jing-fang Lu, Joel R. Eisner, Stephen W. Rafferty, Robert J. Schotzinger, William R. Moore, Christopher J. Logothetis, John C. Araujo, Eleni Efstathiou. Efficacy of VT-464, a novel selective inhibitor of cytochrome P450 17,20-lyase, in castrate-resistant prostate cancer models. AACR (#4772), 2013.
26. Xinhai Wan, Paul Corn, Jun Yang, Eleni Efstathiou, Elsa M. Li Ning Tapia, Fen Wang, Wallace McKeehan, Christopher Logothetis, Patricia Troncoso, Nora M. Navone. Fibroblast growth factor receptor blockade in prostate cancer bone metastases. AACR (#2436), 2013.
27. Dana E. Rathkopf, Matthew R. Smith, Johann Sebastian De Bono, Christopher Logothetis, Neal Shore, Paul L. De Souza, Karim Fizazi, Peter Mulders, Paul N. Mainwaring, John D Hainsworth, Tomasz M. Beer, Scott A. North, Yves Fradet, Thomas W. Griffin, Youn Choi Park, Thian San Kheoh, Eric Jay Small, Howard I. Scher, Arturo Molina, Charles J. Ryan; Memorial Sloan-Kettering Cancer Center, New York, NY; Massachusetts General Hospital Cancer Center, Boston, MA; The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; The University of Texas MD Anderson Cancer Center, Houston, TX; Carolina Urologic Research Center, Myrtle Beach, SC; University of Western Sydney School of Medicine, Ingham Institute, Liverpool, Australia; Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Radboud University Medical Centre, Nijmegen, Netherlands; Haematology and Oncology Clinics of Australia, Brisbane, Australia; Sarah Cannon Research Institute, Nashville, TN; Oregon Health & Science University Knight Cancer Institute, Portland, OR; Cross Cancer Institute, Edmonton, AB, Canada; Laval University, Québec, QC, Canada; Janssen Research & Development, LLC, Los Angeles, CA; Janssen Research & Development, LLC, Raritan, NJ; Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, CA. Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302). ASCO (#5009), 2013.
28. Brittany N. Kleb, Marcos RH Estecio, Guanglin Wu, Jing-Fang Lu, Christopher J. Logothetis, Sankar Maity, Ana M. Aparicio. Mechanism of androgen receptor (AR) silencing in small cell prostate carcinoma. AACR (#2986), 2013.
29. Paul G. Corn, Andreas Varkaris, Elsa M. Li Ning Tapia, John C. Araujo, Ana Aparicio, Shi-Ming Tu, Amado J. Zurita, Eleni Efstathiou, Wei Qiao, Sijin Wen, Gary E. Gallick, Christopher Logothetis; The University of Texas MD Anderson Cancer Center, Houston, TX; West Virginia University Health Science Center, Morgantown, WV. Modulation of soluble c-Met, bone turnover markers, angiogenic factors, and c-Met in men with mCRPC treated with cabozantinib. Genitourinary Cancers Symposium (#58), 2013.
30. John C. Araujo, Geralyn C. Trudel, Fred Saad, Andrew J. Armstrong, Evan Y. Yu, Joaquim Bellmunt, George Wilding, John McCaffrey, Sergio V. Serrano, Vsevolod Matveev, Eleni Efstathiou, Stephane Oudard, Michael J. Morris, Bruce Sizer, Peter J. Goebell, Johann Sebastian De Bono, Prashni Paliwal, Susan Durham, Shinta Cheng, Christopher Logothetis; Department of Genitourinary Medical Onology, University of Texas MD Anderson Cancer Center, Houston, TX; Bristol-Myers Squibb, Montreal, QC, Canada; Centre Hospitalier de l'Universite de Montreal, Montreal, QC, Canada; Duke Cancer Institute and the Duke Prostate Center, Division of Medical Oncology and Urology, Duke University, Durham, NC; University of Washington and Seattle Cancer Care Alliance, Seattle, WA; University Hospital del Mar-IMIM, Barcelona, Spain; University of Wisconsin Carbone Cancer Center, Madison, WI; Irish Clinical Oncology Research Group (ICORG), Dublin, Ireland; Hospital de Cancer de Barretos, Sao Paulo, Brazil; N.N. Blokhin Cancer Research Center, Moscow, Russia; Department of Clinical Therapeutics, The University of Athens, Athens, Greece; Department of Medical Oncology, Georges Pompidou European Hospital, Paris, France; Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY; Essex County Hospital, Colchester, United Kingdom; Department of Urology, Friedrich-Alexander-Universitaet, Erlangen, Germany; Institute of Cancer Research/Royal Marsden Hospital, Sutton, United Kingdom; Bristol-Myers Squibb, Wallingford, CT; Bristol-Myers Squibb, Princeton, NJ. Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial. Genitourinary Cancers Symposium (#LBA8), 2013.
31. Mehmet Asim Bilen, Sue-Hwa Lin, Rosale General, Lance C. Pagliaro, Christopher Logothetis, Ivan Gorlov, Shi-Ming Tu; Baylor College of Medicine, Houston, TX; The University of Texas MD Anderson Cancer Center, Houston, TX. Prediction of a potential lethal phenotype in testicular nonseminomatous germ cell tumor. ASCO (#e15575), 2013.
32. Charles J. Ryan, Anil Londhe, Arturo Molina, Matthew R. Smith, Johann Sebastian De Bono, Peter Mulders, Dana E. Rathkopf, Fred Saad, Christopher Logothetis, Karim Fizazi, Howard I. Scher, Eric Jay Small, Shannon Matheny, Thian San Kheoh, Thomas W. Griffin; Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, CA; Janssen Research & Development, LLC, Raritan, NJ; Janssen Research & Development, LLC, Los Angeles, CA; Massachusetts General Hospital Cancer Center, Boston, MA; The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; Radboud University Medical Centre, Nijmegen, Netherlands; Memorial Sloan-Kettering Cancer Center, New York, NY; University of Montreal, Montreal, QC, Canada; The University of Texas MD Anderson Cancer Center, Houston, TX; Institut Gustave Roussy, University of Paris Sud, Villejuif, France. Relationship of baseline PSA and degree of PSA decline to radiographic progression-free survival (rPFS) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302. ASCO (#5010), 2013.
33. Jeri Kim, John Francis Ward, Curtis A. Pettaway, Xuemei Wang, Deborah A. Kuban, Steven J. Frank, Andrew Lee, Louis L. Pisters, Surena F. Matin, Jay Bakul Shah, Jose A. Karam, Brian Francis Chapin, John N. Papadopoulos, Mary F. Achim, Karen Elizabeth Hoffman, Thomas J. Pugh, Seungtaek Choi, Christopher Logothetis, Patricia Troncoso, John W. Davis; The University of Texas MD Anderson Cancer Center, Houston, TX. Risk of missing advanced stage or high grade tumors during active surveillance (AS) even in favorable-risk prostate cancer (PC). ASCO (#5069), 2013.
34. Farshid Dayyani, Graciela M. Nogueras-Gonzalez, Rebecca Slack, Randall E. Millikan, Amado J. Zurita, John C. Araujo, Gary E. Gallick, Christopher Logothetis, Paul Gettys Corn; The University of Texas MD Anderson Cancer Center, Houston, TX; Essentia Health Cancer Center (Duluth), Duluth, MN. Serum insulin to predict time to castration-resistant progression and overall survival in metastatic androgen-dependent prostate cancer (mADPCa). ASCO (#e16038), 2013.
35. Farshid Dayyani, Andreas Varkaris, John C. Araujo, Jian H. Song, Geralyn C. Trudel, Christopher Logothetis, Gary E. Gallick; The University of Texas MD Anderson Cancer Center, Houston, TX; Bristol-Myers Squibb, Montreal, QC, Canada. Serum insulin-like growth factor-1 levels in response to dasatinib-based regimens in bone-metastatic prostate cancer. Genitourninary Cancers Symposium (#166), 2013.
36. Neal Shore; Ethan Basch; Charles J. Ryan; Peter Mulders; Thian Kheoh; Karim Fizazi; Christopher J. Logothetis; Dana Rathkopf; Matthew R. Smith; Paul N. Mainwaring; Yanni Hao; Thomas Griffin; Susan Li; Michael L. Meyers; Arturo Molina; Charles Cleeland. The impact of abiraterone acetate therapy on patient-reported pain and functional status in chemotherapy-naïve patients with progressive, metastatic castration-resistant prostate cancer – results from an updated analysis. AUA (#784), 2013.
37. Dana E. Rathkopf, Matthew Raymond Smith, Johann Sebastian De Bono, Christopher Logothetis, Neal D. Shore, Paul L. De Souza, Karim Fizazi, Peter Mulders, Paul N. Mainwaring, John D. Hainsworth, Tomasz M. Beer, Scott A. North, Yves Fradet, Thomas W. Griffin, Youn Choi Park, Thian San Kheoh, Eric Jay Small, Howard I. Scher, Arturo Molina, Charles J. Ryan; Memorial Sloan-Kettering Cancer Center, New York, NY; Massachusetts General Hospital Cancer Center, Boston, MA; Institute of Cancer Research/Royal Marsden Hospital, Sutton, United Kingdom; The University of Texas MD Anderson Cancer Center, Houston, TX; Carolina Urologic Research Center, Myrtle Beach, SC; University of Western Sydney School of Medicine, Ingham Institute, Liverpool, Australia; Institut Gustave Roussy, Villejuif, France; Radboud University Medical Centre, Nijmegen, Netherlands; Haematology and Oncology Clinics of Australasia, Brisbane, Australia; Sarah Cannon Research Institute, Nashville, TN; Oregon Health and Science University, Knight Cancer Institute, Portland, OR; Cross Cancer Institute, Edmonton, AB, Canada; Laval University, Québec, QC, Canada; Janssen Research & Development, Los Angeles, CA; Janssen Research & Development, Raritan, NJ; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA; University of California, San Francisco, San Francisco, CA. Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy. Genitourninary Cancers Symposium (#05), 2013.
38. Nallasivam Palanisamy, Jun Yang, Xinhai Wan, John C. Araujo, Eleni Efstathiou, Louis Pisters, Ritu Bhalla, Scott Tomlins, Lakshmi P. Kunju, Arul Chinnaiyan, Christopher J. Logothetis, Patricia Troncoso, Nora M. Navone. Xenografts of human prostate cancer - a genetic profile analysis. AACR (#2780), 2013.

Book Chapters

1. Logothetis CJ. Strategy for the application of therapy in prostate cancer. In: Adv Exp Med Biol. 617, 193-9, 2008. ISBN: 18497043.
2. Logothetis CJ, Moon C. Chapter 225-Endocrine Aspects of Prostate Cancer. In: Principles and Practice of Endocrinology and Metabolism, 2000.
3. Hossan Eand Logothetis CJ. Chapter 10 - Management of hormone refractory disease. In: International Handbook of Prostate Cancer, 137-148, 1999.
4. Logothetis CJ, Vogelzang NJ. Chapter 46B-Current Treatment and Investigative Approaches to the Management of Hormone-Refractory Prostate Cancer. In: Comprehensive Textbook of Genitourinary Oncology, 862-869, 1999.
5. Scher HI, Logothetis CJ. Management of androgen-independent prostatic cancer. In: Principles and Practices of Genitourinary Oncology. Lippincott-Raven, 599-612, 1997.
6. Logothetis CJ. Urological complications of malignancies and cancer therapy. In: Cancer Medicine 4th Edition. 2. Williams and Wilkins, 3191-3196, 1997.
7. Amato RJ, Logothetis CJ. Chemotherapy for stage I and II testicular cancer. In: Comprehensive Textbook of Genitourinary Oncology. Williams and Wilkins, 1022-1027, 1996.
8. Logothetis, CJ, Hoosein NM, Ro JY. Neuroendocrine progression of prostate cancer. In: Comprehensive Textbook of Genitourinary Oncology. Williams and Wilkins, 914-919, 1996.
9. Denis L, Logothetis CJ. Urothelial cancer: The role of haematopoietic growth factors. In: Consultant Series - Urothelial Cancer. Gardiner-Caldwell Biotech, 1996.
10. Sella, A, Finn L, Amato R, Ellerhorst J, Zukiwski A, Kilbourn R, Logothetis CJ. Interferon- (IFN-) Combined with 5-Fluorouracil (5-FU) is an Active Regimen in Metastatic Renal Cell Cancer (RCC). In: Cancer Treatment: An Update. 9891. Springer-Verlag, 535-539, 1994.
11. Amato, R, Finn L, Striegel A, Sella A, Ellerhorst J, Zukiwski A, Logothetis CJ. Salvage therapy in metastatic non-seminomatous germ cell tumour at the University of Texas M. D. Anderson Cancer Center. In: Germ Cell Tumours III, 271-272, 1994.
12. Dexeus F, Logothetis CJ. Penile carcinoma. In: Handbook of Chemotherapy in Clinical Oncology (2nd Edition). Scientific Communication International Ltd., 565-567, 1993.
13. Preti HA, Logothetis CJ. Testicular Cancer. In: Medical Oncology: A Comprehensive Review. PRR, Inc., 295-311, 1993.
14. Logothetis CJ. The management of androgen-independent prostatic carcinoma. In: Prostate Diseases. W. B. Saunders Co, 364-3676, 1993.
15. Sella, A, Amato RJ, Fitz K, Kilbourn RG, Logothetis CJ. Interferon-alpha and 5-fluorouracil combination chemotherapy for metastatic renal cell cancer. In: Interferons and Cytokines. 1, 17-21, 1992.
16. Logothetis CJ. The treatment of chemotherapy refractory metastatic urothelial tumors. In: Urologic Clinics of North America. 19. W. B. Saunders Co., 775-777, 1992.
17. Kilbourn, RG, Owen-Schaub L, Griffith OW, Logothetis CJ. IL-2 mediated hypotension in the awake dog is reversed by inhibitors of nitric oxide formation. In: Second International Meeting - Biology of Nitric Oxide. Portland Press Ltd., 1991.
18. Logothetis, CJ, Chong CD-K, Dexeus FH, Sella A, Ogden S. Intensive chemotherapy for metastatic nonseminomatous germ cell tumors. In: Uro-Oncology: Current Status and Future Trends. Alan R. Liss, Inc., 301-307, 1990.
19. Wallace, S, Charnsangavej C, Carrasco CH, Logothetis CJ. Intra-arterial chemotherapy of genitourinary tumors. In: Clinical Urography. W. B. Saunders Company, 3018-3026, 1990.
20. Logothetis, CJ, Dexeus FH, Chong CD-K, Sella A, Ogden S. The impact of chemotherapy on the survival of patients with metastatic urothelial tumors. In: Uro-Oncology: Current Status and Future Trends. Alan R. Liss, Inc., 107-114, 1990.
21. Dexeus, FH, Logothetis CJ, Sipahi H. Chemotherapy for advanced squamous carcinoma of the male external genital tract and urethra. In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers, 255-259, 1989.
22. Chong C, Logothetis CJ. Chemotherapy for extragonadal germ cell tumors: The M. D. Anderson experience. In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers, 363-369, 1989.
23. Logothetis CJ. CISCA chemotherapy for disseminated bladder carcinoma. In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers, 43-47, 1989.
24. Chong CDK, Logothetis CJ. Cisplatin-based chemotherapy for metastatic pure seminoma. In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers,, 280-285, 1989.
25. Logothetis, CJ, Dexeus F, Chong C, Sella A, Finn L. Cytotoxic chemotherapy for hormone-refractory metastatic prostate cancer. In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers, 234-238, 1989.
26. Logothetis CJ, Ro JY. Germ cell tumors: Clinically relevant advances. In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers, 272-279, 1989.
27. Logothetis, CJ, Johnson DE, von Eschenbach A. Germ cell tumors: Commentary. In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers, 380-384, 1989.
28. Logothetis, CJ, Chong CDK, Ogden S. Long term follow-up of patients treated with cyclic CISCAII/VBIV at the University of Texas M. D. Anderson Cancer Center. In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers, 349-355, 1989.
29. Sella, A, Logothetis CJ, Dexeus FH, Amato RJ, Ogden S. Long-term cure rate in 154 testicular nonseminomatous germ cell tumor (NSGCTT) patients treated with aggressive chemotherapy. In: Proceedings of the 16th International Congress of Chemotherapy. June, 1989.
30. Logothetis CJ. Postoperative adjuvant CISCA chemotherapy for high risk invasive bladder cancer. In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers, 73-76, 1989.
31. Logothetis, CJ, Swanson D, Ogden S. Primary chemotherapy for retroperitoneal nodal disease (clinical stage II). In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers, 326-330, 1989.
32. von Eschenbach, AC, Johnson DE, Logothetis CJ. Prostate cancer: Commentary. In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers,, 251-254, 1989.
33. Johnson, DE, von Eschenbach A, Logothetis CJ. Renal cell carcinoma: Commentary. In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers,, 140-142, 1989.
34. Chong C, Logothetis CJ. Treatment of advanced transitional cell carcinoma of the renal pelvis and ureter. In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers, 94-100, 1989.
35. Johnson, DE, Logothetis CJ, von Eschenbach A. Urinary tract tumors: Commentary. In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers, 101-104, 1989.
36. Logothetis, CJ, Chong C, Dexeus FH, Sella A, Ogden S. Intensive chemotherapy for metastatic nonseminomatous germ cell tumors. In: Uro-Oncology: Current Status and Future Trends. Alan R. Liss, Inc., 301-307, 1988.
37. Swanson DA, Logothetis CJ. Primary chemotherapy for clinical stage II nonseminomatous testicular carcinoma. In: Advances in Urology. Year Book Medical Publishers, Inc., 129-144, 1988.
38. Logothetis, CJ, Johnson DE, Chong C, Dexeus FH, Ogden S, von Eschenbach AC, Ayala AG. Adjuvant CISCA for patients with high risk bladder cancer. In: Adjuvant Therapy of Cancer V. Grune and Stratton, Inc., 565-570, 1987.
39. Swanson DA, Logothetis CJ. Metastatic transitional cell carcinoma. In: Current Therapy in Genitourinary Surgery. B. C. Decker Inc., 69-73, 1987.
40. Logothetis CJ. Testicular cancer. In: Cancer Update 87: Committee of Medical Oncology Fellows Board Review, M. D. Anderson Hospital and Tumor Institute. 1987.
41. Logothetis CJ. Testicular cancer and other tumors of the male genitourinary tract. In: Cancer Chemotherapy by Infusion. 27. Precept Press Inc., 353-367, 1987.
42. Logothetis CJ. Vinblastine and bleomycin combination in the management of germ cell tumors (Part I); Prostatic carcinoma (Part II); Urothelial tumors (Part III). In: Cancer Chemotherapy by Infusion. 27. Precept Press Inc., 353-367, 1987.
43. Logothetis CJ. Extragonadal germ cell tumors. In: Principles and Management of Testicular Cancer. Thieme Inc., 355-350, 1986.
44. Johnson, DE, Logothetis CJ, Zagars GK, Smith DB. Special problems posed by cancer treatments. In: Ostomy Care and the Cancer Patient. Surgical and Clinical Considerations. 8. Grune and Stratton, Inc., 121-131, 1986.
45. Logothetis CJ. Perioperative chemotherapy for the management of primary local regional urothelial tumors. In: Primary Chemotherapy in Cancer Medicine. 201. Alan R. Liss, Inc., 359-366, 1985.
46. Logothetis CJ. Preoperative chemotherapy in the treatment of germinal tumors. In: Primary Chemotherapy in Cancer Medicine. 201. Alan R. Liss, Inc., 341-350, 1985.
47. Logothetis, CJ, von Eschenbach AC, Samuels ML, Trindade A, Johnson DE. Doxorubicin, mitomycin, and 5-FU (DMF) in the treatment of hormone-resistant stage D prostate cancer: A preliminary report. In: Year Book of Cancer, 134-136, 1983.

Letters to the Editor

1. Tu SM, Lin SH, Logothetis C. Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 95(15):1174-5; author reply 1175, 8/2003. PMID: 12902452.
2. von Eschenbach AC, Logothetis CJ. Prostate Cancer. Cancer Bulletin 45(5):379-380, 9/1993.
3. Logothetis CJ, Amato RJ. Dose intensity in germ cell tumors: lessons learned? J Natl Cancer Inst 84(22):1686-7, 11/1992. PMID: 1331481.
4. Logothetis CJ. Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Progress in Clinical and Biological Research. Journal of the National Cancer Institute 83(11):786, 6/1991.
5. Logothetis CJ. Organ Preservation in Bladder Carcinoma: A Matter of Selection. Journal of Clinical Oncology 9(9):1525-1526, 1991.
6. Sella A, Logothetis CJ, Dexeus FH, Amato R. Pulmonary air cyst associated with combination chemotherapy containing bleomycin. AJR Am J Roentgenol 153(1):191, 7/1989. PMID: 2472057.
7. Logothetis CJ. Adjuvant chemotherapy for testicular cancer. N Engl J Med 319(1):53, 7/1988. PMID: 2837667.
8. Logothetis CJ. Carcinoma-in-situ of the testis. Lancet 2(8565):977, 10/1987. PMID: 2889904.
9. Logothetis CJ. Have aggressive chemotherapy regimens improved results in advanced germ cell tumors. Eur J Cancer Clin Oncol 23(9):1415-6, 9/1987. PMID: 2445581.
10. Logothetis CJ. Lhermittes sign following cisplatin therapy for a patient with CISCAII/VBIV (editorial). American Journal of Medicine 82(3):575-576, 3/1987.
11. Logothetis CJ, Samuels ML. Prognostic factors in disseminated germ cell tumors. J Clin Oncol 4(8):1278-80, 8/1986. PMID: 3016207.
12. Logothetis CJ. Endodermal sinus tumors. Chest 88(1):6-7, 7/1985. PMID: 2408823.
13. Logothetis CJ. Bladder cancer histology reported to influence response to treatment (editorial). Urology Times 1:380, 4/1984.

Grant & Contract Support

Title: MD Anderson Cancer Center Prostate Cancer SPORE
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Duration: 5/1/2015 - 4/30/2020
 
Title: From Prognostication to Prediction: A Comprehensive Characterization of Murine and Clinical m-CRPC from “Microenvironment Dependence” to Aggressive Variants
Funding Source: Prostate Cancer Foundation-Clinical Challenge
Role: Co-Principal Investigator
Duration: 10/1/2014 - 9/30/2016
 
Title: Evidence-based Decision Making Facilitates Personalized Treatment Plans for Advanced Prostate Cancer
Funding Source: Roswell Park (DOD-Transformative Impact)
Role: Collaborator
Principal Investigator: Mohler
Duration: 7/1/2014 - 6/30/2017
 
Title: Osteocrines in Therapy Resistance of Prostate Cancer Bone Metastasis: Evaluation of Strategies to Overcome Therapy Resistance from Tumor-Educated Bone Environment
Funding Source: Prostate Cancer Foundation-Janssen Special Challenge Award
Role: Co-Principal Investigator
Duration: 4/4/2014 - 4/3/2016
 
Title: Stanford and Joan Alexander Tissue Derivatives Fund
Funding Source: The Stanford and Joan Alexander Foundation
Role: Principal Investigator
Duration: 1/27/2012 - 1/26/2015
 
Title: Individualized Microenvironment Targeted Therapy for Prostate Cancer Bone Metastases: Simultaneous Evaluation of Multiple Therapeutic Targets
Funding Source: Prostate Cancer Foundation - Creativity Award
Role: Principal Investigator
Duration: 1/11/2010 - 1/10/2012
 
Title: MD Anderson Cancer Center Prostate Cancer SPORE
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/2/2009 - 8/31/2014
 
Title: M. D. Anderson Cancer Center Prostate Cancer Research Program Clinical Consortium Award
Funding Source: Department of Defense (DOD)
Role: Principal Investigator
Duration: 9/1/2009 - 8/31/2014
 
Title: Cancer Center Support (CORE) Grant-RP-16-Prostate and Genitourinary Program
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 7/1/2008 - 6/30/2018
 
Title: 3T Perflurocarbon-filled Endorectal Magnetic Resonance Spectroscopic Imaging of Prostate (CT)
Funding Source: DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role: Co-Investigator
Principal Investigator: Choi
Duration: 1/8/2007 - 2/7/2011
 
Title: Marcus Foundation Agreement (PP-5)
Funding Source: Marcus Foundation
Role: Co-Investigator
Principal Investigator: Bast
Duration: 7/10/2006 - 7/9/2009
 
Title: Novel Anti-PSMA Antibody-Based Paclitaxel Copolymer Prodrugs for Intraprostatic Treatment of Localized Prostatic Carcinoma
Funding Source: US Department of Defense
Role: Co-Investigator
Principal Investigator: Klostergaard
Duration: 9/23/2004 - 10/22/2007
 
Title: U10 Full Member Application Affiliated with SWOG
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Lippman
Duration: 7/26/2004 - 12/31/2009
 
Title: Prostate Cancer Foundation Clinical Research Consortium
Funding Source: Prostate Cancer Foundation
Role: Principal Investigator
Duration: 9/1/2002 - 12/31/2008
 
Title: The Clinical Development of Thalidomide as an Angiogenesis Inhibitor Therapy for Prostate Cancer
Funding Source: DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role: Principal Investigator
Duration: 9/28/2001 - 10/22/2007
 
Title: The University of Texas M. D. Anderson SPORE in Prostate Cancer
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 6/1/2001 - 12/31/2007

Last updated: 7/28/2014